

# CITATION REPORT

List of articles citing

## Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

DOI: 10.1056/nejmoa043330

New England Journal of Medicine, 2005, 352, 987-96.

**Source:** <https://exaly.com/paper-pdf/39264673/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2240	High-grade gliomas. 156-169		
2239	Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. 37-52		1
2238	Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. <b>1992</b> , 33, 469		1
2237	Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. <b>1994</b> , 20, 301		2
2236	Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. <b>1994</b> , 20, 1283		0
2235	RAF expression in human astrocytic tumors. <b>1998</b> , 23, 17		
2234	Administraç�o intranasal do agente antitumoral �cool perf�co: estrat�gia terap�utica para pacientes com glioblastoma recidivado: Comunicaç�o preliminar. <b>2005</b> , 24, 85-92		
2233	Treatment of astrocytomas. <b>2005</b> , 18, 632-8		19
2232	An update on oligodendroglial neoplasms. <b>2005</b> , 18, 639-44		8
2231	10 questions about temozolomide and the treatment of brain tumors. <b>2005</b> , 11, 362-5		5
2230	Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. <b>2005</b> , 17, 581-90		60
2229	Coagulation biology in glioma pathogenesis: a missing link?. <b>2005</b> , 3, 1915-6		6
2228	News. <b>2005</b> , 14, 304-309		
2227	Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. <b>2005</b> , 116, 187-92		37
2226	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <b>2005</b> , 104, 1478-86		73
2225	Caspase 8 is absent or low in many ex vivo gliomas. <b>2005</b> , 104, 1487-96		40
2224	Secondary Ph+ acute lymphoblastic leukemia after temozolomide. <b>2005</b> , 84, 760-2		37

2223	12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas. <b>2005</b> , 181, 500-6	20
2222	Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. <b>2005</b> , 181, 372-7	69
2221	Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. <b>2005</b> , 117, 821-6	12
2220	Oligodendroglioma. <b>2005</b> , 7, 305-314	5
2219	The role of radiosurgery in the management of malignant brain tumors. <b>2005</b> , 6, 501-8	7
2218	Targeted molecular therapy of malignant gliomas. <b>2005</b> , 5, 186-97	44
2217	Optimal role of temozolomide in the treatment of malignant gliomas. <b>2005</b> , 5, 198-206	142
2216	Neuro-Oncology in a Nutshell. <b>2005</b> , 72, 93-93	
2215	Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. <b>2005</b> , 207, 224-31	126
2214	Potential of PET in oncology and radiotherapy. <b>2005</b> , Supplement_28, 6-16	5
2213	An era of rapid advancement: diagnosis and treatment of metastatic brain cancer. <b>2005</b> , 57, S5-9; discussion S1-4	290
2212	The potential of proton beam radiation therapy in intracranial and ocular tumours. <b>2005</b> , 44, 862-70	9
2211	Chemotherapy for brain tumors--a new beginning. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1036-8	59.2 75
2210	Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. <b>2005</b> , 16, 1702-8	129
2209	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. <b>2005</b> , 16 Suppl 1, i64-5	37
2208	Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. <b>2005</b> , 11, 6767-71	129
2207	Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. <b>2005</b> , 11, 6722-9	16
2206	In Reply:. <b>2005</b> , 23, 8272-8275	4

2205	Drug Insight: temozolomide as a treatment for malignant glioma—impact of a recent trial. <b>2005</b> , 1, 88-95	46
2204	The molecular epidemiology of gliomas in adults. <b>2005</b> , 19, E5	50
2203	Avoiding glucocorticoid administration in a neurooncological case. <b>2005</b> , 4, 1186-9	9
2202	Temozolomide: a milestone in the pharmacotherapy of brain tumors. <b>2005</b> , 1, 747-54	27
2201	Treatment of brain tumors. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2350-3; author reply 2350-3	59.2 11
2200	Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. <b>2005</b> , 102, 16759-64	253
2199	Immunotherapy for human glioma: innovative approaches and recent results. <b>2005</b> , 5, 777-90	34
2198	Treatment of adults with recurrent malignant glioma. <b>2005</b> , 5, 509-14	13
2197	Brain tumors: controversies and challenges in management. <b>2005</b> , 5, 1-2	1
2196	Chemotherapy for malignant glioma. <b>2005</b> , 5, S41-9	7
2195	[Standards and new developments in the chemotherapy of glioblastomas]. <b>2005</b> , 130, 2270-4	
2194	MATHEMATICAL MODELLING OF GLIOBLASTOMA TUMOUR DEVELOPMENT: A REVIEW. <b>2005</b> , 15, 1779-1794	92
2193	Emerging targeted treatments for malignant glioma. <b>2005</b> , 10, 845-54	4
2192	Health-related quality of life and symptom research in glioblastoma multiforme patients. <b>2005</b> , 5, 763-74	11
2191	How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. <b>2005</b> , 23, 4235-6; author reply 4236	43
2190	Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. <b>2005</b> , 65, 7429-35	168
2189	Glioblastoma treatment with temozolomide plus radiotherapy. <b>2005</b> , 2, 228-229	
2188	The role of radio- and chemotherapy in glioblastoma. <b>2005</b> , 28, 315-7	62

2187	Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy. <b>2005</b> , 5, 683-90	5
2186	High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. <b>2005</b> , 6, 953-60	66
2185	Health-related quality of life in patients with glioblastoma: a randomised controlled trial. <b>2005</b> , 6, 937-44	246
2184	Quality of life for patients with glioblastoma. <b>2005</b> , 6, 913-4	
2183	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. <b>2005</b> , 23, 9359-68	286
2182	Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. <b>2005</b> , 7, 883-93	38
2181	MGMT gene silencing and benefit from temozolomide in glioblastoma. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 997-1003	59.2 5267
2180	Novel therapeutics in adult malignant brain gliomas. <b>2005</b> , 14, 643-58	4
2179	Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. <b>2005</b> , 23, 8863-9	238
2178	Commentary. <b>2005</b> , 12, 921	
2177	Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma. <b>2005</b> , 65, 819-20	
2176	Insoluble fibrin may reduce turbulence and bind blood components into clots. <b>2005</b> , 65, 820-1	8
2175	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. <b>2005</b> , 31, 577-81	1
2174	Health related quality of life outcomes in cancer clinical trials. <b>2005</b> , 41, 1697-709	116
2173	[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy]. <b>2005</b> , 9, 322-31	4
2172	Targeting energy metabolism in brain cancer: review and hypothesis. <b>2005</b> , 2, 30	160
2171	Boron neutron capture therapy of cancer: current status and future prospects. <b>2005</b> , 11, 3987-4002	761
2170	Gene therapy for malignant glioma: current clinical status. <b>2005</b> , 12, 585-98	163

2169	Radiosensitizers in Brain Cancer. <b>2006</b> , 5, 363-370	1
2168	Treatment of Newly Diagnosed Glioblastoma with Concomitant and Adjuvant Temozolomide and Radiotherapy. <b>2006</b> , 5, 427-432	
2167	New and emerging radiosensitizers and radioprotectors. <b>2006</b> , 24, 444-56	30
2166	Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology. <b>2006</b> ,	1
2165	Glioma oncogenesis and animal models of glioma formation. <b>2006</b> , 20, 1193-214	3
2164	Role of radiation therapy in pediatric cancer. <b>2006</b> , 20, 455-70	25
2163	Drug delivery to brain tumours: challenges and progress. <b>2006</b> , 3, 499-509	27
2162	Hyperthermia in Cancer Treatment: A Primer. <b>2006</b> ,	40
2161	Treatments for astrocytic tumors in children: current and emerging strategies. <b>2006</b> , 8, 167-78	40
2160	New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. <b>2006</b> , 6, 1129-31	2
2159	Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. <b>2006</b> , 6, 1593-607	30
2158	Glioma-specific antigens for immune tumor therapy. <b>2006</b> , 5, 793-802	11
2157	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. <b>2006</b> , 24, 2715-22	583
2156	Chemotherapy in the treatment of malignant gliomas. <b>2006</b> , 6, 755-67	13
2155	Oligodendroglial tumors. <b>2006</b> , 6, 519-32	7
2154	Diffuse brainstem glioma in children: critical review of clinical trials. <b>2006</b> , 7, 241-8	441
2153	Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. <b>2006</b> , 7, 392-401	2287
2152	Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. <b>2006</b> , 7, 436-8	36

2151	Temozolomide: a novel treatment for pituitary carcinoma. <b>2006</b> , 7, 518-20	135
2150	A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. <b>2006</b> , 66, 10815-23	96
2149	Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. <b>2006</b> , 5, 783-91	57
2148	Glioblastoma multiforme: advances in postsurgical management. <b>2006</b> , 3, 678-683	4
2147	Inroads in managing malignant gliomas renew hope. <b>2006</b> , 3, 684	
2146	HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. <b>2006</b> , 8, 889-95	64
2145	[Cerebral gliomas: imaging diagnosis and follow-up]. <b>2006</b> , 87, 779-91	4
2144	[Management of malignant gliomas diagnosed during pregnancy]. <b>2006</b> , 162, 322-9	21
2143	Current role of radiation therapy in the management of malignant brain tumors. <b>2006</b> , 20, 431-53	5
2142	Recent advances in the treatment of malignant astrocytoma. <b>2006</b> , 24, 1253-65	258
2141	Chemotherapy and the treatment of brain metastases. <b>2006</b> , 20, 1287-95	9
2140	The changing management of low-grade astrocytomas and oligodendrogliomas. <b>2006</b> , 20, 1249-66	6
2139	[Multiple gliomas: clinical studies and pathophysiological hypothesis]. <b>2006</b> , 162, 845-51	9
2138	A changing paradigm of glioma biology. <b>2006</b> , 20, 1171-91	1
2137	Neurosurgery in the elderly: brain tumors and subdural hematomas. <b>2006</b> , 22, 623-44	11
2136	Blood-brain barrier and chemotherapeutic treatment of brain tumors. <b>2006</b> , 6, 1199-209	108
2135	Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. <b>2006</b> , 24, 4412-7	131
2134	A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. <b>2006</b> , 49, 1800-7	29

2133	Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <b>2006</b> , 24, 2707-14	592
2132	Advances toward an understanding of brainstem gliomas. <b>2006</b> , 24, 1266-72	194
2131	Molecular pathology of gliomas. <b>2006</b> , 12, 394-402	10
2130	Critical role of the FERM domain in Pyk2 stimulated glioma cell migration. <b>2006</b> , 349, 939-47	25
2129	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. <b>2006</b> , 32, 74-89	137
2128	Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma. <b>2006</b> , 32, 483-6	4
2127	Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. <b>2006</b> , 17, 129-39	154
2126	Recent developments in the use of chemotherapy in brain tumours. <b>2006</b> , 42, 582-8	95
2125	Neural stem cells as novel cancer therapeutic vehicles. <b>2006</b> , 42, 1298-308	39
2124	Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. <b>2006</b> , 42, 2335-42	75
2123	Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. <b>2006</b> , 42, 3294-303	57
2122	Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. <b>2006</b> , 13, 747-51	30
2121	Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. <b>2006</b> , 33, 399-407	1
2120	Central nervous system tumors. <b>2006</b> , 1, 475-513	3
2119	Chemotherapy of High-Grade Astrocytomas. <b>2006</b> , 347-363	
2118	Temozolomide chemotherapy in patients with recurrent malignant gliomas. <b>2006</b> , 21, 739-44	11
2117	Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. <b>2006</b> , 15, 1569	2
2116	Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. <b>2006</b> , 16, 127	2



2115	Temozolomide and Radiotherapy as First-Line Treatment of High-Grade Gliomas. <b>2006</b> , 92, 299-305	10
2114	Exploiting Apoptosis Pathways for Glioblastoma Therapy. 1033-1048	
2113	Glioma and Other Neuroepithelial Neoplasms. <b>2006</b> , 674-694	
2112	Management of glioma in Victoria (1998-2000): retrospective cohort study. <b>2006</b> , 184, 270-3	46
2111	Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. <b>2006</b> , 16, 33	7
2110	Current status of clinical trials for glioblastoma. <b>2006</b> , 1, 265-81	18
2109	Boron Neutron Capture Therapy. <b>2006</b> ,	
2108	The safety of the temozolomide in patients with malignant glioma. <b>2006</b> , 1, 205-22	14
2107	Clinical studies with targeted toxins in malignant glioma. <b>2006</b> , 1, 119-31	24
2106	'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. <b>2006</b> , 65, 529-39	369
2105	Combined modality treatment of glioblastoma multiforme: the role of temozolomide. <b>2006</b> , 1, 43-51	15
2104	The role of chemotherapy in the treatment of malignant astrocytomas. <b>2006</b> , 33, 127-40	11
2103	Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme. <b>2006</b> , 1, 37-52	2
2102	Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. <b>2006</b> , 1, 245-51	21
2101	Tumor hypoxia and prognosis in human gliomas. <b>2006</b> , 12, 451-4	3
2100	Glioma therapy in adults. <b>2006</b> , 12, 279-92	93
2099	Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. <b>2006</b> , 17, 969-75	12
2098	New approaches to primary brain tumor treatment. <b>2006</b> , 17, 1003-16	36

2097	Recent advances in immunotherapy for human glioma. <b>2006</b> , 18, 631-6	37
2096	Molecular changes in brain tumors: prognostic and therapeutic impact. <b>2006</b> , 18, 623-30	11
2095	Glioma in the elderly. <b>2006</b> , 18, 644-7	20
2094	Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. <b>2006</b> , 16, 1093	3
2093	Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. <b>2006</b> , 144, 337-43	355
2092	New treatments for malignant gliomas: careful evaluation and cautious optimism required. <b>2006</b> , 144, 371-3	15
2091	A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. <b>2006</b> , 16, 1117	2
2090	Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. <b>2006</b> , 59, 1078-85; discussion 1085	17
2089	Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. <b>2006</b> , 15, 1163	
2088	Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. <b>2006</b> , 28, 1531	0
2087	Conditionally replicative adenoviral vectors for malignant glioma. <b>2006</b> , 16, 99-115	19
2086	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <b>2006</b> , 96, 766-76	253
2085	The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. <b>2006</b> , 2, 6-8	4
2084	POSTER ABSTRACTS. <b>2006</b> , 2, A145-A179	
2083	An update on the first decade of the European centralized procedure: how many innovative drugs?. <b>2006</b> , 62, 610-6	46
2082	Brain tumour stem cells. <b>2006</b> , 6, 425-36	799
2081	Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. <b>2006</b> , 94, 1853-63	13
2080	Fatty acid synthase: a novel target for antiglioma therapy. <b>2006</b> , 95, 869-78	51

2079	Chemotherapy resistance of glioblastoma stem cells. <b>2006</b> , 13, 1238-41	497
2078	PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells. <b>2006</b> , 13, 469-78	10
2077	Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. <b>2006</b> , 13, 539-54	37
2076	Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. <b>2006</b> , 25, 2909-19	55
2075	Identification of expressed genes characterizing long-term survival in malignant glioma patients. <b>2006</b> , 25, 5994-6002	85
2074	Angiogenesis in malignant glioma--a target for antitumor therapy?. <b>2006</b> , 59, 181-93	70
2073	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <b>2006</b> , 60, 99-111	30
2072	Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. <b>2006</b> , 60, 181-93	85
2071	Age and bromodeoxyuridine labelling index as prognostic factors in high-grade gliomas treated with surgery and radiotherapy. <b>2006</b> , 18, 459-65	2
2070	Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. <b>2006</b> , 64, 869-75	30
2069	Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. <b>2006</b> , 64, 876-85	113
2068	Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. <b>2006</b> , 65, 499-508	322
2067	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. <b>2006</b> , 65, 1192-9	79
2066	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. <b>2006</b> , 65, 788-99	22
2065	A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. <b>2006</b> , 65, 1422-8	79
2064	Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. <b>2006</b> , 66, 179-86	50
2063	Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. <b>2006</b> , 66, 331-8	41
2062	Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures. <b>2006</b> , 66, 263-70	16

2061	Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. <b>2006</b> , 66, 818-24	46
2060	(131)I- <i>chtnt-1/B</i> mAb: tumour necrosis therapy for malignant astrocytic glioma. <b>2006</b> , 6, 539-45	37
2059	Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. <b>2006</b> , 6, 733-54	36
2058	Chemotherapy Resistance. <b>2006</b> , 89-104	0
2057	Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. <b>2006</b> , 24, 2851-7	70
2056	Brain cancer diagnosis and therapy with nanoplatforms. <b>2006</b> , 58, 1556-77	248
2055	Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. <b>2006</b> , 24, 177-80	6
2054	Role of MIB1 in predicting survival in patients with glioblastomas. <b>2006</b> , 76, 193-200	42
2053	Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. <b>2006</b> , 76, 313-9	68
2052	Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. <b>2006</b> , 77, 33-45	16
2051	Phase II trial of temozolomide in children with recurrent high-grade glioma. <b>2006</b> , 77, 89-94	43
2050	Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. <b>2006</b> , 77, 219-20	3
2049	The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. <b>2006</b> , 78, 7-14	354
2048	TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. <b>2006</b> , 78, 161-71	48
2047	Cystemustine in recurrent high grade glioma. <b>2006</b> , 79, 33-7	7
2046	A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. <b>2006</b> , 78, 311-6	38
2045	High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. <b>2006</b> , 78, 321-6	16
2044	Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. <b>2006</b> , 79, 9-17	12

2043	Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study. <b>2006</b> , 80, 107-8	22
2042	Complications of a temozolomide overdose: a case report. <b>2006</b> , 80, 57-61	9
2041	Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death. <b>2006</b> , 80, 111-21	21
2040	Concomitant bone marrow metastasis of a glioblastoma multiforme revealed at the diagnosis. <b>2006</b> , 148, 997-1000	14
2039	Nebenwirkungen der Therapie von Hirntumoren. <b>2006</b> , 12, 546-555	1
2038	Diagnostik und Therapie des Glioblastoms. <b>2006</b> , 12, 500-507	
2037	Anaplastische Gliome. <b>2006</b> , 12, 508-517	
2036	Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. <b>2006</b> , 118, 230-8	5
2035	[Palliative therapy in glioblastoma multiforme: a multimodal concept]. <b>2006</b> , 156, 255-9	
2034	Malignant glioma: neuropathology and neurobiology. <b>2006</b> , 156, 332-7	41
2033	[Malignant gliomas--radiotherapy]. <b>2006</b> , 156, 342-5	
2032	Chemotherapy for malignant gliomas. <b>2006</b> , 156, 346-50	4
2031	Gender aspects of treatment and drug related toxicity in medical oncology. <b>2006</b> , 156, 534-40	7
2030	Clinical aspects of molecular biology for the diagnosis and treatment of esophageal cancer. <b>2006</b> , 3, 91-94	
2029	Role of temozolomide in pediatric brain tumors. <b>2006</b> , 22, 652-61	31
2028	Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: analysis of hypoxia and vascular parameters of regrowing tumors. <b>2006</b> , 182, 408-14	11
2027	Glioblastoma in the elderly: current and future trends. <b>2006</b> , 60, 256-66	34
2026	Thallium-201SPECT assessment in the detection of recurrences of treated gliomas and ependymomas. <b>2006</b> , 8, 750-4	6

2025	Spanish co-operative group of Medical Neuro-oncology (GENOM). <b>2006</b> , 8, 770	
2024	The Spanish Group of Medical Neuro-Oncology. GENOM. <b>2006</b> , 8, 388-90	
2023	Chemotherapeutic options for primary brain tumors. <b>2006</b> , 7, 467-78	14
2022	Recent advances in the treatment of oligodendrogliomas. <b>2006</b> , 6, 212-7	2
2021	Advances in the treatment of primary brain tumors: dawn of a new era?. <b>2006</b> , 8, 45-9	7
2020	The evolution of chemoradiation for glioblastoma: a modern success story. <b>2006</b> , 8, 50-3	5
2019	Correlative studies in neuro-oncology trials: should they influence treatment?. <b>2006</b> , 8, 54-7	5
2018	Targeted molecular therapy of malignant gliomas. <b>2006</b> , 8, 58-70	28
2017	Low-grade gliomas: the debate continues. <b>2006</b> , 8, 71-7	9
2016	Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. <b>2006</b> , 165, 121-34	11
2015	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. <b>2006</b> , 166, 46-55	19
2014	Neuro-oncology: setting new standards of management. <b>2006</b> , 5, 8-9	1
2013	Novel radiation-enhancing agents in malignant gliomas. <b>2006</b> , 16, 29-37	22
2012	Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. <b>2006</b> , 6, 133	66
2011	Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). <b>2006</b> , 6, 247	32
2010	A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. <b>2006</b> , 6, 29	22
2009	Prognostic impact of molecular markers in a series of 220 primary glioblastomas. <b>2006</b> , 106, 2218-23	117
2008	Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <b>2006</b> , 107, 162-70	47

2007	Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. <b>2006</b> , 107, 1348-54	120
2006	Prognostic stratification of patients with anaplastic gliomas according to genetic profile. <b>2006</b> , 107, 1891-7	59
2005	Glioblastoma-derived tumorspheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. <b>2006</b> , 54, 850-60	225
2004	Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. <b>2006</b> , 118, 2594-601	28
2003	Photodynamic therapy of brain tumors--a work in progress. <b>2006</b> , 38, 384-9	88
2002	Radioimmunotherapy of brain tumor. <b>2006</b> , 28, 518-22	39
2001	In vivo optical imaging using quantum dots for the management of brain tumors. <b>2006</b> , 6, 879-90	36
2000	Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines. <b>2006</b> , 5, 1211-7	14
1999	Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. <b>2006</b> , 5, 93-9	21
1998	Long term responses with cetuximab therapy in glioblastoma multiforme. <b>2006</b> , 5, 912-4	41
1997	Long term responses with cetuximab therapy in glioblastoma multiforme. <b>2006</b> , 5, 1242-3	2
1996	Potential of antiglioma effect with combined temozolomide and interferon- $\gamma$ . <b>2006</b> , 16, 1253	1
1995	Holiday heart syndrome possibly triggered after the start of radiochemotherapy for glioblastoma multiforme. <b>2006</b> , 105, 86-8	1
1994	Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. <b>2006</b> , 12, 3843-50	111
1993	Using molecular information to guide brain tumor therapy. <b>2006</b> , 2, 232-3	11
1992	Glioblastoma--more questions than answers?. <b>2006</b> , 3, 60-1	1
1991	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. <b>2006</b> , 129, 2426-35	107
1990	Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. <b>2006</b> , 6, 679-95	15

1989	Treatment options for glioblastoma. <b>2006</b> , 20, E19	34
1988	New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. <b>2006</b> , 20, E6	57
1987	When should radiotherapy for low-grade glioma be given--immediately after surgery or at the time of progression?. <b>2006</b> , 3, 136-7	3
1986	Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. <b>2006</b> , 3, 339-43; quiz following 343	35
1985	Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie. <b>2006</b> , 38, 133-135	2
1984	Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. <b>2006</b> , 17, 1592-7	40
1983	Brain tumors: molecular biology and targeted therapies. <b>2006</b> , 17 Suppl 10, x191-7	20
1982	Treatment of glioblastoma multiforme: a new standard. <b>2006</b> , 63, 337-41	41
1981	Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. <b>2006</b> , 98, 1546-57	79
1980	Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). <b>2006</b> , 17, 952-6	82
1979	Early genetic changes involved in low-grade astrocytic tumor development. <b>2006</b> , 6, 645-50	17
1978	Synergistic Effect of Immunotherapy and Chemotherapy in Cancers: Perspective in High Grade Glioma Treatment. <b>2006</b> , 3, 513-523	
1977	Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. <b>2006</b> , 24, 2563-9	377
1976	Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. <b>2006</b> , 24, 190-205	95
1975	Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. <b>2006</b> , 8, 280-3	52
1974	Autophagy, the Trojan horse to combat glioblastomas. <b>2006</b> , 20, E7	95
1973	Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?. <b>2006</b> , 105, 739-44	13
1972	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. <b>2006</b> , 8, 253-60	59



1971	Past, present, and future strategies in the treatment of high-grade glioma in children. <b>2006</b> , 24, 77-81	31
1970	Surviving glioblastoma for more than 5 years: the patient's perspective. <b>2006</b> , 66, 239-42	60
1969	Diffusely infiltrative low-grade gliomas in adults. <b>2006</b> , 24, 1236-45	76
1968	Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. <b>2006</b> , 28, 527-31	30
1967	Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. <b>2006</b> , 24, 115-22	165
1966	Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. <b>2006</b> , 103, 5799-804	200
1965	CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. <b>2006</b> , 12, 6765-71	113
1964	Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. <b>2006</b> , 98, 38-50	125
1963	O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. <b>2006</b> , 24, 3431-7	152
1962	Changing paradigms--an update on the multidisciplinary management of malignant glioma. <b>2006</b> , 11, 165-80	316
1961	Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future. <b>2006</b> , 7, 749-65	4
1960	Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Soci� Fran�aise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. <b>2006</b> , 24, 5259-64	50
1959	Diagnosis and treatment of recurrent high-grade astrocytoma. <b>2006</b> , 24, 1273-80	153
1958	Adjuvant treatment of high grade gliomas. <b>2006</b> , 17 Suppl 10, x186-90	10
1957	Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. <b>2006</b> , 5, 239-50	55
1956	PCV chemotherapy for recurrent glioblastoma. <b>2006</b> , 66, 587-9	64
1955	Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. <b>2006</b> , 12, 1970-82	134
1954	Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <b>2006</b> , 67, 544-5; author reply 544-5	2

1953	Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. <b>2006</b> , 12, 860-8	173
1952	Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. <b>2006</b> , 8, 67-78	177
1951	Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas. <b>2006</b> , 5, 201-13	9
1950	Molecular diagnostics as a tool to personalize treatment in adult glioma patients. <b>2006</b> , 5, 215-29	14
1949	Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. <b>2006</b> , 24, 1627-32	61
1948	Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. <b>2006</b> , 24, 3871-9	64
1947	A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. <b>2006</b> , 66, 3987-91	328
1946	Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. <b>2006</b> , 70, 1524-33	89
1945	Role of ABC transporters in the chemoresistance of human gliomas. <b>2006</b> , 6, 433-45	56
1944	The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. <b>2006</b> , 12, 5174-81	16
1943	Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. <b>2006</b> , 5, 2531-9	76
1942	In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. <b>2006</b> , 12, 4523-32	64
1941	Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. <b>2006</b> , 105, 385-91	74
1940	New treatment strategies for malignant gliomas. <b>2006</b> , 6, 1087-104	108
1939	Biological Basis of Combined Radio- and Chemotherapy. <b>2006</b> , 3-17	2
1938	Present and potential future issues in glioblastoma treatment. <b>2006</b> , 6, 719-32	98
1937	Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. <b>2006</b> , 6, 1481-94	20
1936	Targeted modulation of MGMT: clinical implications. <b>2006</b> , 12, 328-31	192

1935	Oncolytic adenoviruses as antiglioma agents. <b>2006</b> , 6, 697-708	22
1934	Temozolomide: a milestone in neuro-oncology and beyond?. <b>2006</b> , 6, 1187-204	64
1933	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <b>2006</b> , 95, 1155-60	193
1932	Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. <b>2006</b> , 95, 862-8	22
1931	Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. <b>2006</b> , 6, 1585-92	24
1930	Quality of randomized controlled trials reporting in the primary treatment of brain tumors. <b>2006</b> , 24, 1136-44	77
1929	Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. <b>2006</b> , 5, 1248-55	62
1928	Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. <b>2006</b> , 24, 401-6	428
1927	Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. <b>2006</b> , 24, 274-87	117
1926	Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. <b>2006</b> , 24, 5427-33	83
1925	Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. <b>2006</b> , 24, 5271-6	105
1924	Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. <b>2006</b> , 12, 4738-46	170
1923	Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. <b>2006</b> , 11, 152-64	175
1922	Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. <b>2007</b> , 25, 1470-5	159
1921	Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. <b>2007</b> , 37, 897-906	48
1920	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. <b>2007</b> , 25, 4722-9	1119
1919	Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. <b>2007</b> , 13, 566-575	120
1918	Glioblastoma multiforme: evidence-based approach to therapy. <b>2007</b> , 7, S23-7	27

1917	Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. <b>2007</b> , 13, 2592-8	92
1916	Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. <b>2007</b> , 25, 1651-7	250
1915	GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. <b>2007</b> , 104, 8053-8	63
1914	Methylguanine methyltransferase testing in glioblastoma: when and how?. <b>2007</b> , 25, 1459-60	40
1913	Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. <b>2007</b> , 282, 21206-12	168
1912	The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage. <b>2007</b> , 282, 6061-7	23
1911	Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. <b>2007</b> , 13, 1253-9	896
1910	O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. <b>2007</b> , 67, 580-4	66
1909	A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. <b>2007</b> , 6, 3208-18	79
1908	ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. <b>2007</b> , 13, 2728-37	631
1907	Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. <b>2007</b> , 96, 960-9	27
1906	Molecularly targeted therapies for malignant gliomas: advances and challenges. <b>2007</b> , 7, 641-61	32
1905	Long-term survival with glioblastoma multiforme. <b>2007</b> , 130, 2596-606	624
1904	Management of glioblastoma. <b>2007</b> , 8, 3133-46	34
1903	Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. <b>2007</b> , 7, 675-87	61
1902	Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. <b>2007</b> , 13, 6252-6	45
1901	The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. <b>2007</b> , 9, 47-52	78
1900	Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. <b>2007</b> , 83, 677-85	33

1899	Malignant glioma drug discovery - targeting protein kinases. <b>2007</b> , 2, 1-17	18
1898	Prophylactic radiotherapy for glioblastoma in the elderly. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 195; author reply 196	59.2 2
1897	Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. <b>2007</b> , 25, 4075-83	56
1896	Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. <b>2007</b> , 9, 354-63	92
1895	Antiangiogenic therapy in malignant glioma: promise and challenge. <b>2007</b> , 13, 3545-58	36
1894	Modulation of gene transcription by natural products--a viable anticancer strategy. <b>2007</b> , 13, 2744-50	15
1893	N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. <b>2007</b> , 6, 467-70	45
1892	Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. <b>2007</b> , 72, 302-7	22
1891	Aiding and ABT'ing Treatment for Glioblastoma. <b>2007</b> , 6, 802-4	1
1890	Venous thromboembolism and survival in patients with high-grade glioma. <b>2007</b> , 9, 89-95	104
1889	New developments in the treatment of malignant gliomas. <b>2007</b> , 7, 1313-26	17
1888	Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment. <b>2007</b> , 2, 147-50	22
1887	Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. <b>2007</b> , 15, 2140-5	28
1886	Fatal reactivation of hepatitis B with temozolomide. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1591-259.2	28
1885	Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. <b>2007</b> , 6, 679-85	43
1884	Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. <b>2007</b> , 106, 601-8	190
1883	Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report. <b>2007</b> , 6, 447-50	6
1882	On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. <b>2007</b> , 80, 32-7	46

1881	Resection versus radiosurgery for patients with brain metastases. <b>2007</b> , 3, 95-102	11
1880	Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. <b>2007</b> , 9, 259-70	72
1879	Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas. <b>2007</b> , 39, 154-160	17
1878	Brain tumors: current issues in diagnosis and management. <b>2007</b> , 27, 312-24	8
1877	Emerging therapies for malignant glioma. <b>2007</b> , 7, S29-36	13
1876	Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthotopic tumors. <b>2007</b> , 167, 289-97	41
1875	Pediatric CNS tumors: current treatment and future directions. <b>2007</b> , 7, 1029-42	18
1874	Multimodality management of brain metastases in metastatic melanoma patients. <b>2007</b> , 7, 1699-705	6
1873	Brain Metastases. <b>2007</b> ,	2
1872	Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. <b>2007</b> , 13, 7155-65	68
1871	Inhibition of histone deacetylation: a strategy for tumor radiosensitization. <b>2007</b> , 25, 4051-6	141
1870	Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p53 DNA binding. <b>2007</b> , 67, 6889-98	31
1869	The rationale for and the current role of chemoradiotherapy. <b>2007</b> , 6, 11-19	6
1868	Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. <b>2007</b> , 13, 6603-9	48
1867	International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. <b>2007</b> , 25, 5082-6	79
1866	In Reply. <b>2007</b> , 25, 3550-3551	2
1865	Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. <b>2007</b> , 67, 4467-73	107
1864	Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. <b>2007</b> , 25, 399-404	70

1863	Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. <b>2007</b> , 25, 837-44	285
1862	The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. <b>2007</b> , 99, 639-52	41
1861	Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <b>2007</b> , 25, 3357-61	208
1860	Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. <b>2007</b> , 25, 2601-6	149
1859	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2007</b> , 18 Suppl 2, ii69-70	11
1858	Survey of treatment recommendations for anaplastic oligodendroglioma. <b>2007</b> , 9, 314-8	89
1857	Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. <b>2007</b> , 25, 4922-8	18
1856	Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. <b>2007</b> , 67, 11886-95	87
1855	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. <b>2007</b> , 67, 3545-50	136
1854	Cerebrospinal fluid spread of anaplastic glioma. <b>2007</b> , 25, 596-7	4
1853	ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. <b>2007</b> , 67, 8255-63	55
1852	Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. <b>2007</b> , 67, 8791-9	56
1851	Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. <b>2007</b> , 13, 7133-8	18
1850	Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. <b>2007</b> , 69, 1366-73	93
1849	Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. <b>2007</b> , 6, 169-76	5
1848	Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. <b>2007</b> , 6, 375-82	27
1847	Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. <b>2007</b> , 9, 240-4	6
1846	DNA repair after irradiation in glioma cells and normal human astrocytes. <b>2007</b> , 9, 404-11	42

1845	Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. <b>2007</b> , 67, 11499-504	108
1844	AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. <b>2007</b> , 13, 6735-42	129
1843	Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation. <b>2007</b> , 13, 5195-201	60
1842	Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. <b>2007</b> , 13, 6217-23	26
1841	MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. <b>2007</b> , 6, 1212-22	90
1840	Lessons learned in the development of targeted therapy for malignant gliomas. <b>2007</b> , 6, 1909-19	162
1839	The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. <b>2007</b> , 6, 2449-57	38
1838	Neurosurgical management of intramedullary spinal cord tumors in children. <b>2007</b> , 43, 222-35	56
1837	Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. <b>2007</b> , 99, 936-48	38
1836	The use of temozolomide as a radiosensitizer for the treatment of newly diagnosed glioblastoma multiforme. <b>2007</b> , 6, 103-110	
1835	Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. <b>2007</b> , 47, 341-9; discussion 350	22
1834	Prognostic factors in elderly patients with supratentorial malignant gliomas. <b>2007</b> , 47, 543-9; discussion 549	8
1833	Galectin-1 expression in human glioma cells: Modulation by ionizing radiation and effects on tumor cell proliferation and migration. <b>2007</b> , 18, 483	5
1832	Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. <b>2007</b> , 8, 47-60	61
1831	Modern Approaches to Radiation Therapy. <b>2007</b> ,	
1830	The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. <b>2007</b> , 17, 941	2
1829	Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. <b>2007</b> , 30, 701	5
1828	Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. <b>2007</b> , 30, 1263	5



1827	Photodynamic therapy of malignant glioma with hypericin: Comprehensive in vitro study in human glioblastoma cell lines. <b>2007,</b>	3
1826	Conventional Chemotherapeutics. <b>2007,</b>	
1825	Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. <b>2007,</b>	
1824	Nanoparticles for Thermootherapy. <b>2007,</b>	2
1823	Radiochemotherapy for brain metastasis: how to define a role for temozolomide. <b>2007, 30, 350-1</b>	2
1822	In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. <b>2007, 30, 789-97</b>	60
1821	Hepatic mitochondrial function and brain tumours. <b>2007, 10, 475-9</b>	6
1820	Incorporating molecular tools into clinical trials and treatment for gliomas?. <b>2007, 20, 708-11</b>	8
1819	Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. <b>2007, 61, E880-2; discussion E882</b>	33
1818	Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. <b>2007, 61, 1031-7; discussion 1037-8</b>	114
1817	Immunotherapy for Gliomas. <b>2007, 29, 6</b>	
1816	Editorial: what is new in the treatment of gliomas?. <b>2007, 20, 704-7</b>	8
1815	Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta. <b>2007, 30, 261-73</b>	19
1814	Failure of immunotherapy and chemotherapy for a patient with primary choroidal melanoma. <b>2007, 1, 30-2</b>	1
1813	Immunotherapy for Gliomas. <b>2007, 29, 8</b>	
1812	New chemotherapy options for the treatment of malignant gliomas. <b>2007, 18, 621-32</b>	15
1811	Immunotherapy for Gliomas. <b>2007, 29, 1-6</b>	1
1810	Molecular targeted therapies and chemotherapy in malignant gliomas. <b>2007, 19, 598-605</b>	40

1809	New molecular targets in malignant gliomas. <b>2007</b> , 20, 712-8	30
1808	Immunotherapy for Gliomas. <b>2007</b> , 29, 1-6	2
1807	Management of scalp toxic epidermal necrolysis and cranial osteomyelitis with serratus anterior myocutaneous pedicle flap: a case report. <b>2007</b> , 28, 524-9	5
1806	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <b>2007</b> , 19, 606-11	48
1805	Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. <b>2007</b> , 13, 335-44	26
1804	Predictive and prognostic markers in neuro-oncology. <b>2007</b> , 66, 1074-81	29
1803	Treatment for posterior fossa dissemination of primary supratentorial glioma. <b>2007</b> , 106, 567-74	4
1802	Chemotherapy and delivery in the treatment of primary brain tumors. <b>2007</b> , 2, 197-211	9
1801	Spinal metastasis in glioblastoma multiforme: a case study. <b>2007</b> , 39, 21-5	7
1800	Coincidence vs cause: cure in three glioblastoma patients treated with brachytherapy. <b>2007</b> , 34, 339-42	9
1799	Temozolomide-Associated Organizing Pneumonitis. <b>2007</b> , 82, 771-773	11
1798	Adjuvant chemotherapy for adults with malignant glioma: a systematic review. <b>2007</b> , 34, 402-10	22
1797	Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. <b>2007</b> , 25, 3485-91	31
1796	Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. <b>2007</b> , 67, 388-91	95
1795	Insulin-like growth factor type I biology and targeting in malignant gliomas. <b>2007</b> , 145, 795-811	87
1794	Targeted alpha-particle radiotherapy with <sup>211</sup> At-labeled monoclonal antibodies. <b>2007</b> , 34, 779-85	90
1793	2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. <b>2007</b> , 50, 4122-34	113
1792	A rapid assay for drug sensitivity of glioblastoma stem cells. <b>2007</b> , 358, 908-13	25

1791	Potential biochemical therapy of glioma cancer. <b>2007</b> , 362, 225-9	26
1790	The human subventricular zone: a source of new cells and a potential source of brain tumors. <b>2007</b> , 205, 313-24	111
1789	Role of Wnt5a in the proliferation of human glioblastoma cells. <b>2007</b> , 257, 172-81	87
1788	Targeting malignant glioma survival signalling to improve clinical outcomes. <b>2007</b> , 14, 301-8	77
1787	Slowly progressive hemiparesis. <b>2007</b> , 14, 1007-1008	
1786	[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. <b>2007</b> , 36, 1249-54	2
1785	Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation?. <b>2007</b> , 82, 119-22	36
1784	High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. <b>2007</b> , 85, 371-8	32
1783	Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. <b>2007</b> , 12, 1395-403	205
1782	Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells. <b>2007</b> , 79, 8423-30	55
1781	Inhibiting kinases in malignant gliomas. <b>2007</b> , 11, 473-96	34
1780	Análisis de la presencia de mutaciones por pérdida de heterocigocidad de 1p/19q en tumores cerebrales de estirpe glial. <b>2007</b> , 18, 285-293	2
1779	4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. <b>2007</b> , 9, 358-69	72
1778	Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. <b>2007</b> , 9, 882-92	119
1777	Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. <b>2007</b> , 17, 201-12	182
1776	Tumors of the Brain and Spine. <b>2007</b> ,	9
1775	Central nervous system tumors. <b>2007</b> , 82, 1271-86	197
1774	Operative Neuromodulation. <b>2007</b> ,	3

1773	Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. <b>2007</b> , 21, 583-7	26
1772	Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail. <b>2007</b> , 7, 663-74	22
1771	Serum GFAP is a diagnostic marker for glioblastoma multiforme. <b>2007</b> , 130, 3336-41	155
1770	Antiangiogenic agents for the treatment of glioblastoma. <b>2007</b> , 16, 1895-908	22
1769	The economics of temozolomide in brain cancer. <b>2007</b> , 8, 1923-9	4
1768	Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. <b>2007</b> , 68, 688-90	69
1767	CNS complications of breast cancer: current and emerging treatment options. <b>2007</b> , 21, 559-79	23
1766	Temozolomide treatment of an adult with a relapsing medulloblastoma. <b>2007</b> , 25, 470-5	19
1765	CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. <b>2007</b> , 28, 1264-8	94
1764	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. <b>2007</b> , 13, 2038-45	318
1763	The status of gene therapy for brain tumors. <b>2007</b> , 7, 197-208	35
1762	Adjuvant therapy in glioblastomas: false steps and real advances. <b>2007</b> , 7, 607-8	1
1761	Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. <b>2007</b> , 25, 776-84	14
1760	The course of neurocognitive functioning in high-grade glioma patients. <b>2007</b> , 9, 53-62	128
1759	Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis. <b>2007</b> , 21, 775-87	30
1758	Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. <b>2007</b> , 52, 3291-306	85
1757	Chemoradiotherapy in malignant glioma: standard of care and future directions. <b>2007</b> , 25, 4127-36	385
1756	Diagnosis and treatment of high-grade astrocytoma. <b>2007</b> , 25, 1111-39, x	74

1755	Cerebral blood flow increase in cancer patients by applying cervical spinal cord stimulation. <b>2007</b> , 18, 28-32; discussion 33-5	6
1754	Novel therapies for malignant gliomas. <b>2007</b> , 25, 1141-71, x	13
1753	Anaplastic oligodendroglioma and oligoastrocytoma. <b>2007</b> , 25, 1089-109, ix-x	39
1752	Temozolomide-Associated Organizing Pneumonitis. <b>2007</b> , 82, 771-773	10
1751	Advances in radiation therapy for brain tumors. <b>2007</b> , 25, 1005-33, ix	22
1750	Management of patients with low-grade gliomas. <b>2007</b> , 25, 1073-88, ix	12
1749	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. <b>2007</b> , 5, 67	89
1748	Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. <b>2007</b> , 5, 68	25
1747	Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). <b>2007</b> , 4, 175-86	175
1746	Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. <b>2007</b> , 3, 682-93	87
1745	Proteomic analysis of gliomas. <b>2007</b> , 21, 576-82	24
1744	Clinical applications of PET in brain tumors. <b>2007</b> , 48, 1468-81	299
1743	Inhibition of angiogenesis and invasion in malignant gliomas. <b>2007</b> , 7, 1537-60	44
1742	Targeted Brain Tumor Treatment-Current Perspectives. <b>2007</b> , 2, 117739280700200	8
1741	Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. <b>2007</b> ,	7
1740	Efficacy of Different Regimens of Adjuvant Radiochemotherapy for Treatment of Glioblastoma. <b>2007</b> , 93, 31-36	10
1739	TUMORS OF THE BRAIN. <b>2007</b> , 1324-1339	
1738	Brain tumour treatments: the view of patients and caregivers. <b>2007</b> , 3, 194-196	1

1737	Prognostic Implication of Clinical and Pathologic Features in Patients with Glioblastoma Multiforme Treated with Concomitant Radiation plus Temozolomide. <b>2007</b> , 93, 248-256	44
1736	Chemoradiotherapy in High-Grade Gliomas. <b>2007</b> , 93, 526-526	1
1735	In Reply. <b>2007</b> , 93, 526-526	
1734	Synergistic antiglioma activity of radiotherapy and enzastaurin. <b>2007</b> , 61, 153-61	67
1733	Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. <b>2007</b> , 120, 1782-6	9
1732	Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. <b>2007</b> , 121, 901-7	43 <sup>1</sup>
1731	BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. <b>2008</b> , 122, 1778-86	90
1730	Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. <b>2008</b> , 122, 1981-6	47
1729	Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. <b>2007</b> , 29, 874-84	47
1728	Molecularly targeted therapy for malignant glioma. <b>2007</b> , 110, 13-24	245
1727	Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. <b>2007</b> , 110, 1542-50	158
1726	Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. <b>2007</b> , 9, 151-60	43
1725	Therapeutic management of metastatic brain tumors. <b>2007</b> , 61, 70-8	31
1724	Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. <b>2007</b> , 19, 177-81	23
1723	A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide. <b>2007</b> , 19, 269	
1722	Defining the standard of care for high-grade glioma--a NICE deal for UK patients?. <b>2007</b> , 19, 507-8	4
1721	Predicting outcome of patients with high-grade gliomas after radiotherapy using quantitative analysis of T1-weighted magnetic resonance imaging. <b>2007</b> , 67, 1476-83	6
1720	GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. <b>2007</b> , 68, 159-65	41

1719	Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. <b>2007</b> , 68, 441-8	47
1718	Neural stem cells: implications for the conventional radiotherapy of central nervous system malignancies. <b>2007</b> , 68, 324-33	61
1717	Neural stem cell-preserving external-beam radiotherapy of central nervous system malignancies. <b>2007</b> , 68, 978-85	71
1716	Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. <b>2007</b> , 68, 1396-401	33
1715	In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. <b>2007</b> , 68, 873-82	32
1714	Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. <b>2007</b> , 69, 381-9	68
1713	Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. <b>2007</b> , 69, 475-82	104
1712	Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. <b>2007</b> , 69, 820-4	95
1711	Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. <b>2007</b> , 69, 825-30	28
1710	Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. <b>2007</b> , 69, 831-8	35
1709	In Reply to Dr. Nieder. <b>2007</b> , 69, 641	
1708	In Reply to Dr. Nieder. <b>2007</b> , 69, 641	
1707	What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448). <b>2007</b> , 69, 640-1; author reply 641	2
1706	Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. <b>2007</b> , 69, 1246-53	56
1705	5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts. <b>2007</b> , 69, 1254-61	10
1704	The attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative study. <b>2007</b> , 6, 7	33
1703	Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. <b>2007</b> , 2, 26	40
1702	Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice. <b>2007</b> , 2, 38	11

1701	Endothelial cell KIT expression in human tumours. <b>2007</b> , 211, 481-8	26
1700	Temozolomide in pediatric low-grade glioma. <b>2007</b> , 49, 808-11	46
1699	High-grade gliomas: babies are not small adults!. <b>2007</b> , 49, 879-80	3
1698	Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. <b>2007</b> , 26, 186-97	383
1697	Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. <b>2007</b> , 26, 4084-94	116
1696	Glioblastoma multiforme: the role of DSB repair between genotype and phenotype. <b>2007</b> , 26, 7809-15	23
1695	DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. <b>2007</b> , 14, 548-58	276
1694	Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. <b>2007</b> , 14, 45-56	36
1693	Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. <b>2007</b> , 14, 550-60	32
1692	Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. <b>2007</b> , 14, 1045-54	49
1691	HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. <b>2007</b> , 14, 1143-51	21
1690	The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. <b>2007</b> , 97, 302-7	83
1689	The neuro-steroid, 3beta androstene 17alpha diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways. <b>2007</b> , 97, 619-27	12
1688	Targeting brain-tumor stem cells. <b>2007</b> , 25, 193-4	66
1687	Congenital glioblastoma: a clinicopathologic and genetic analysis. <b>2007</b> , 17, 276-81	47
1686	Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. <b>2008</b> , 18, 164-71	45
1685	Why we will need to learn new skills to control cancer. <b>2007</b> , 37, 201-4	2
1684	Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. <b>2007</b> , 122, 615-22	45



1683	Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. <b>2007</b> , 98, 1226-33	62
1682	Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. <b>2007</b> , 3, 071011204603001-???	
1681	Radiotherapeutic alternatives for previously irradiated recurrent gliomas. <b>2007</b> , 7, 167	65
1680	Human primary brain tumor cell growth inhibition in serum-free medium optimized for neuron survival. <b>2007</b> , 1157, 156-66	9
1679	Inhibiting catalase activity sensitizes 36B10 rat glioma cells to oxidative stress. <b>2007</b> , 42, 787-97	51
1678	DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. <b>2007</b> , 6, 1100-15	135
1677	Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells. <b>2007</b> , 58, 247-53	10
1676	Systems biology and cancer stem cells. <b>2008</b> , 12, 97-110	21
1675	Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. <b>2007</b> , 123, 172-8	75
1674	Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. <b>2007</b> , 4, 172-80	111
1673	Peptide-based immunotherapeutic approaches to glioma: a review. <b>2007</b> , 7, 645-9	13
1672	Predicting patterns of glioma recurrence using diffusion tensor imaging. <b>2007</b> , 17, 1675-84	79
1671	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <b>2007</b> , 21, 2683-710	1682
1670	Net clinical benefit: functional endpoints in brain tumor clinical trials. <b>2007</b> , 9, 60-5	14
1669	Therapeutic advances for glioblastoma multiforme: current status and future prospects. <b>2007</b> , 9, 66-70	46
1668	Impact of molecular profiling on clinical trial design for glioblastoma. <b>2007</b> , 9, 71-9	8
1667	CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. <b>2007</b> , 183, 563-70	45
1666	Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. <b>2007</b> , 183, 695-702	28

1665	The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. <b>2007</b> , 85, 497-509	67
1664	Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. <b>2007</b> , 60, 643-50	71
1663	O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines. <b>2007</b> , 60, 883-9	2
1662	Molecular targets of glioma invasion. <b>2007</b> , 64, 458-78	307
1661	Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. <b>2007</b> , 81, 53-60	533
1660	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. <b>2007</b> , 81, 271-7	54
1659	Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. <b>2007</b> , 81, 287-94	73
1658	Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. <b>2007</b> , 81, 323-5	
1657	Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. <b>2007</b> , 82, 81-3	275
1656	Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. <b>2007</b> , 82, 85-9	32
1655	Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models. <b>2007</b> , 82, 41-7	23
1654	Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide. <b>2007</b> , 82, 113-6	10
1653	Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. <b>2007</b> , 82, 177-81	14
1652	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. <b>2007</b> , 82, 207-9	32
1651	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. <b>2007</b> , 82, 273-9	15
1650	Pattern of recurrence in paediatric malignant glioma: an institutional experience. <b>2007</b> , 83, 279-84	12
1649	MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. <b>2007</b> , 83, 173-9	75
1648	Pulsed reduced dose-rate radiotherapy: case report : a novel re-treatment strategy in the management of recurrent glioblastoma multiforme. <b>2007</b> , 83, 307-11	29

1647	Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?. <b>2007</b> , 84, 71-7	13
1646	Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. <b>2007</b> , 84, 179-83	9
1645	The combined effects of multiple chemotherapeutic agents for malignant glioma cells. <b>2007</b> , 84, 31-7	6
1644	Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. <b>2007</b> , 84, 201-11	10
1643	Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. <b>2007</b> , 84, 119-29	14
1642	Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. <b>2007</b> , 84, 131-40	25
1641	Radiosensitizing potential of the selective cyclooxygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. <b>2007</b> , 85, 25-31	23
1640	Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. <b>2007</b> , 85, 105-7	32
1639	Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment-case study and review of literature. <b>2007</b> , 85, 229-30	28
1638	Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. <b>2007</b> , 85, 171-80	62
1637	Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. <b>2007</b> , 85, 181-9	12
1636	Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. <b>2007</b> , 85, 217-22	9
1635	Delay in radiotherapy shortens survival in patients with high grade glioma. <b>2007</b> , 85, 339-43	81
1634	Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis. <b>2007</b> , 32, 2194-202	33
1633	Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. <b>2007</b> , 149, 245-52; discussion 252-3	93
1632	Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions. <b>2007</b> , 32, 373-9	7
1631	Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. <b>2007</b> , 32, 359-71	40
1630	Diffuse glioma growth: a guerilla war. <b>2007</b> , 114, 443-58	422

1629 Anaplastic oligodendroglioma. **2007**, 7, 189-90

1628 Cannabinoids and gliomas. **2007**, 36, 60-7

69

1627 Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment. **2007**, 9, 797-803

17

1626 A mathematical model of the treatment and survival of patients with high-grade brain tumours. **2007**, 245, 112-24

32

1625 First experience in 5-ALA fluorescence-guided and endoscopically assisted microsurgery of brain tumors. **2008**, 23, 202-208

16

1624 Oligodendroglioma. **2008**, 66, 262-72

52

1623 Brain tumor stem cells. **2008**, 32, 124-42

20

1622 Radiation dose is predictive of biochemical failure, local failure, and distant metastases. In regard to Kupelian et Al. (Int J Radiat Oncol Biol Phys 2008;71:16-22). **2008**, 72, 1621-2; author reply 1622

1

1621 Carnosine Inhibits Growth of Cells Isolated from Human Glioblastoma Multiforme. **2008**, 14, 127-135

32

1620 Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. **2008**, 87, 143-51

29

1619 Outcome and tolerability of topiramate in brain tumor associated epilepsy. **2008**, 86, 61-70

62

1618 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. **2008**, 87, 71-8

75

1617 Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. **2008**, 87, 79-84

12

1616 A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. **2008**, 87, 85-90

36

1615 Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. **2008**, 87, 155-64

39

1614 Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. **2008**, 87, 103-9

96

1613 Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. **2008**, 87, 51-61

32

1612 Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. **2008**, 87, 287-94

74

1611	Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. <b>2008</b> , 88, 1-9	34
1610	The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. <b>2008</b> , 88, 43-50	25
1609	Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. <b>2008</b> , 88, 57-63	39
1608	Expression of TLR9 within human glioblastoma. <b>2008</b> , 88, 19-25	42
1607	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. <b>2008</b> , 88, 97-103	163
1606	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <b>2008</b> , 88, 105-13	31
1605	Glioblastoma multiforme with an abscess: case report and literature review. <b>2008</b> , 88, 221-5	10
1604	Time course of imaging changes of GBM during extended bevacizumab treatment. <b>2008</b> , 88, 339-47	96
1603	A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. <b>2008</b> , 88, 353-7	46
1602	Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. <b>2008</b> , 89, 97-103	111
1601	Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. <b>2008</b> , 89, 113-8	70
1600	A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. <b>2008</b> , 89, 187-93	12
1599	Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. <b>2008</b> , 89, 205-10	73
1598	Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. <b>2008</b> , 89, 219-24	112
1597	Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. <b>2008</b> , 89, 339-57	15
1596	Diagnosis of malignant glioma: role of neuropathology. <b>2008</b> , 89, 287-311	74
1595	Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. <b>2008</b> , 89, 239-46	48
1594	FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. <b>2008</b> , 90, 47-51	11

1593	Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. <b>2008</b> , 90, 89-97	91
1592	A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. <b>2008</b> , 90, 229-35	30
1591	Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. <b>2008</b> , 90, 181-9	19
1590	Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. <b>2008</b> , 90, 309-14	40
1589	Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. <b>2008</b> , 90, 315-9	14
1588	Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. <b>2008</b> , 57, 1827-35	29
1587	A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. <b>2008</b> , 61, 653-9	55
1586	Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. <b>2008</b> , 61, 1059-67	38
1585	Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells. <b>2008</b> , 62, 407-16	21
1584	Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. <b>2008</b> , 184, 572-9	38
1583	Hochmaligne Gliome im Kindes- und Jugendalter. <b>2008</b> , 156, 1201-1207	6
1582	[Chemotherapy for brain tumors in adult patients]. <b>2008</b> , 79, 231-41	2
1581	Aktuelle Standards in der Behandlung maligner Gliome. <b>2008</b> , 1, 36-38	
1580	Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <b>2008</b> , 1, 11-16	
1579	The emerging role of anti-angiogenic therapy for malignant glioma. <b>2008</b> , 9, 1-22	27
1578	Targeting the epidermal growth factor receptor in high-grade astrocytomas. <b>2008</b> , 9, 23-31	43
1577	Immunotherapeutic treatment strategies for primary brain tumors. <b>2008</b> , 9, 32-40	10
1576	Abstracts. <b>2008</b> , 9, 1-122	0

1575	Use of complementary and alternative medical therapy by patients with primary brain tumors. <b>2008</b> , 8, 264-8	18
1574	Glioblastoma multiforme. <b>2008</b> , 10, 285-94	7
1573	Anaplastic oligodendroglioma. <b>2008</b> , 10, 295-307	16
1572	Cancer stem cells and brain tumors. <b>2008</b> , 10, 262-7	24
1571	Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. <b>2008</b> , 2, 183-193	1
1570	Adult high-grade malignant gliomas. <b>2008</b> , 2, 195-198	
1569	Brain tumor stem cells as research and treatment targets. <b>2008</b> , 25, 67-72	31
1568	Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience. <b>2008</b> , 29, 77-83	8
1567	Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. <b>2008</b> , 31, 141-55; discussion 155	32
1566	Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. <b>2008</b> , 24, 293-302	41
1565	Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. <b>2008</b> , 115, 249-59	56
1564	Parotid gland metastasis from glioblastoma multiforme: a case report and review of the literature. <b>2008</b> , 265, 709-11	14
1563	Natural history and management of brainstem gliomas in adults. A retrospective Italian study. <b>2008</b> , 255, 171-7	69
1562	The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. <b>2008</b> , 3, 32	39
1561	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. <b>2008</b> , 3, 44	91
1560	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. <b>2008</b> , 1, 52	153
1559	Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. <b>2008</b> , 50, 976-82	56
1558	The diet-derived sulforaphane inhibits matrix metalloproteinase-9-activated human brain microvascular endothelial cell migration and tubulogenesis. <b>2008</b> , 52, 692-700	32

1557	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. <b>2008</b> , 112, 1337-44	37
1556	Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. <b>2008</b> , 112, 2267-73	125
1555	Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. <b>2008</b> , 112, 2046-51	123
1554	Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. <b>2008</b> , 112, 2038-45	18
1553	Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. <b>2008</b> , 113, 405-10	336
1552	External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial. <b>2008</b> , 113, 559-65	4
1551	Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. <b>2008</b> , 113, 841-6	48
1550	Temozolomide for recurrent low-grade spinal cord gliomas in adults. <b>2008</b> , 113, 1019-24	49
1549	Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. <b>2008</b> , 113, 1953-68	590
1548	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. <b>2008</b> , 113, 2139-45	70
1547	Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. <b>2008</b> , 113, 2152-7	96
1546	A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. <b>2008</b> , 113, 2532-8	15
1545	Chemotherapy for glioblastoma: is costly better?. <b>2008</b> , 113, 2617-22	6
1544	Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. <b>2008</b> , 113, 2779-89	66
1543	Management of malignant gliomas during pregnancy: a case series. <b>2008</b> , 113, 3349-54	39
1542	MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. <b>2008</b> , 122, 1391-9	76
1541	Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. <b>2008</b> , 123, 357-364	106
1540	Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. <b>2008</b> , 123, 787-92	72



1539	Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. <b>2008</b> , 123, 1215-8	18
1538	Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARgamma agonists. <b>2008</b> , 217, 93-102	15
1537	CPEB1 regulates beta-catenin mRNA translation and cell migration in astrocytes. <b>2008</b> , 56, 1401-13	32
1536	Patterns of care in elderly glioblastoma patients. <b>2008</b> , 64, 628-34	156
1535	Glioblastoma in the elderly: an age-old problem. <b>2008</b> , 64, 597-9	9
1534	Glioblastoma in adults. <b>2008</b> , 67, 139-52	126
1533	DNA methylation: its role in cancer development and therapy. <b>2008</b> , 32, 187-235	47
1532	Erythropoietin augments survival of glioma cells after radiation and temozolomide. <b>2008</b> , 72, 927-34	18
1531	Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. <b>2008</b> , 72, 1188-97	153
1530	In Reply to Dr. Jalali. <b>2008</b> , 72, 1622-1623	
1529	Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005). <b>2008</b> , 72, 1622; author reply 1622-3	
1528	Open low-field magnetic resonance imaging for target definition, dose calculations and set-up verification during three-dimensional CRT for glioblastoma multiforme. <b>2008</b> , 20, 157-67	10
1527	Defining the standard of care for high-grade glioma--a NICE deal for patients. <b>2008</b> , 20, 97-8	2
1526	The potential clinical advantages of charged particle radiotherapy using protons or light ions. <b>2008</b> , 20, 555-63	22
1525	Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. <b>2008</b> , 70, 987-92	121
1524	Reirradiation tolerance of the human brain. <b>2008</b> , 70, 1350-60	193
1523	Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. <b>2008</b> , 70, 773-81	66
1522	Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. <b>2008</b> , 71, 999-1005	39

1521	Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. <b>2008</b> , 71, 1372-80	151
1520	A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. <b>2008</b> , 72, 900-4	5
1519	Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. <b>2008</b> , 71, 507-16	29
1518	Radiation-induced malignant gliomas: is there a role for reirradiation? In regard to Paulino et Al. (Int j radiat oncol biol phys epub 2008 feb 8). <b>2008</b> , 72, 304-5; author reply 305	
1517	Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. <b>2008</b> , 72, 383-9	78
1516	Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. <b>2008</b> , 15, 2887-93	186
1515	An integrated genomic analysis of human glioblastoma multiforme. <b>2008</b> , 321, 1807-12	4419
1514	Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. <b>2008</b> , 73, 421-6	25
1513	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. <b>2008</b> , 70, 779-87	702
1512	An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. <b>2008</b> , 117, 191-7	29
1511	Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?. <b>2008</b> , 17, 383-94	42
1510	Immunotherapy of malignant brain tumors. <b>2008</b> , 222, 70-100	73
1509	Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. <b>2008</b> , 15, 1233-9	67
1508	Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. <b>2008</b> , 21, 308-15	83
1507	Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. <b>2008</b> , 15, 723-32	14
1506	Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. <b>2008</b> , 15, 823-31	19
1505	The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. <b>2008</b> , 27, 2091-6	160
1504	Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. <b>2008</b> , 98, 1830-8	28

1503	In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. <b>2008</b> , 99, 294-304	17
1502	Survival from brain tumours in England and Wales up to 2001. <b>2008</b> , 99 Suppl 1, S102-3	3
1501	Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. <b>2008</b> , 10, 1470-6	3575
1500	DNA repair pathways as targets for cancer therapy. <b>2008</b> , 8, 193-204	1164
1499	CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. <b>2008</b> , 18, 370-7	123
1498	Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. <b>2008</b> , 18, 520-32	157
1497	Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. <b>2008</b> , 99, 1656-62	11
1496	Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H <sub>2</sub> O <sub>2</sub> . <b>2008</b> , 45, 1178-89	48
1495	Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. <b>2008</b> , 75, 1083-92	73
1494	Methylation status of MGMT gene promoter in meningiomas. <b>2008</b> , 187, 25-7	26
1493	BMPing off glioma stem cells. <b>2008</b> , 13, 3-4	29
1492	Novel anti-angiogenic therapies for malignant gliomas. <b>2008</b> , 7, 1152-60	183
1491	Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. <b>2008</b> , 130, 146-53	99
1490	Neurological oncology. <b>2008</b> , 36, 609-615	1
1489	Bevacizumab: a treatment option for recurrent glioblastoma multiforme. <b>2008</b> , 42, 1486-90	32
1488	Brain tumor stem cells: bringing order to the chaos of brain cancer. <b>2008</b> , 26, 2916-24	142
1487	ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. <b>2008</b> , 57, 214-22	26
1486	Anti-apoptosis mechanisms in malignant gliomas. <b>2008</b> , 26, 493-500	82

1485	Cancer stem cells and glioma. <b>2008</b> , 4, 427-35	97
1484	Malignant gliomas in adults. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 492-507	59.2 3070
1483	Radiation oncology advances: an introduction. <b>2008</b> , 139, 1-4	3
1482	Radiotherapy and temozolomide in glioblastoma: Predictive factors of response to the treatment. <b>2008</b> , 6, 136-137	
1481	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. <b>2008</b> , 27, 86	80
1480	The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. <b>2008</b> , 10, 198-206	87
1479	Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. <b>2008</b> , 10, 1383-92	93
1478	[Radiotherapy of adult glial tumors: new developments and perspectives]. <b>2008</b> , 164, 531-41	0
1477	Chemotherapy for malignant brain tumors of childhood. <b>2008</b> , 23, 1149-59	69
1476	Hypericin uptake: a prognostic marker for survival in high-grade glioma. <b>2008</b> , 15, 778-83	11
1475	The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000. <b>2008</b> , 15, 398-401	14
1474	Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. <b>2008</b> , 15, 1-8	18
1473	Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. <b>2008</b> , 15, 114-21	66
1472	Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT. <b>2008</b> , 15, 1327-34	29
1471	Invadopodia: at the cutting edge of tumour invasion. <b>2008</b> , 15, 725-37	169
1470	Gliomagenesis and neural stem cells: Key role of hypoxia and concept of tumor "neo-niche". <b>2008</b> , 70, 96-104	23
1469	Cell- and peptide-based immunotherapeutic approaches for glioma. <b>2008</b> , 14, 228-35	58
1468	Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. <b>2008</b> , 60, 40-9	64

1467	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <b>2008</b> , 20, 267-75	133
1466	Recent advances in the treatment of central nervous system tumors. <b>2008</b> , 3, 49-79	2
1465	Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. <b>2008</b> , 26, 1764-72	11
1464	Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. <b>2008</b> , 69, 506-9; discussion 509	78
1463	Commentary. <b>2008</b> , 69, 509	
1462	Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. <b>2008</b> , 70 Suppl 1, S1:60-3	6
1461	Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. <b>2008</b> , 17, 173-84	95
1460	Boron neutron capture therapy for glioblastoma. <b>2008</b> , 262, 143-52	103
1459	[Minutes of the 49th Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles (USA), October 28-November 1 2007]. <b>2008</b> , 12, 68-72	0
1458	[The effect of waiting list for radiotherapy for glioblastoma]. <b>2008</b> , 12, 497-9	10
1457	[Should elderly patients with glioblastoma be proposed to radiotherapy?]. <b>2008</b> , 12, 827-30	7
1456	[Radiation therapy for glial tumors: technical aspects and clinical indications]. <b>2008</b> , 12, 687-94	9
1455	[Perspectives in diagnosis and management of malignant gliomas]. <b>2008</b> , 12, 695-700	0
1454	Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). <b>2008</b> , 44, 1210-6	40
1453	The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. <b>2008</b> , 44, 2133-43	18
1452	Targeting TRAIL death receptors. <b>2008</b> , 8, 433-9	32
1451	DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?. <b>2008</b> , 34, 558-67	107
1450	Malignancy and neurofibromatosis type 1: balancing treatment risks/benefits and expected prognosis. <b>2008</b> , 5, 546	

1449	Designer therapies for glioblastoma multiforme. <b>2008</b> , 1142, 108-32	83
1448	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <b>2008</b> , 9, 29-38	407
1447	Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. <b>2008</b> , 24, 3239-57	73
1446	Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). <b>2008</b> , 88, 183-91	96
1445	Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. <b>2008</b> , 86, 419-27	28
1444	Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. <b>2008</b> , 88, 177-82	26
1443	Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. <b>2008</b> , 6, 80	192
1442	Nomograms as clinicobiological predictors of survival in glioblastoma. <b>2008</b> , 9, 5-6	8
1441	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. <b>2008</b> , 9, 453-61	834
1440	[Histological and molecular classification of gliomas]. <b>2008</b> , 164, 505-15	25
1439	Constitutive activation of Raf-1 induces glioma formation in mice. <b>2008</b> , 10, 501-10	56
1438	"MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management?. <b>2008</b> , 10, 308-10	6
1437	Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. <b>2008</b> , 8, 343-59	43
1436	Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. <b>2008</b> , 10, 332-7	145
1435	[Gliomas in the elderly]. <b>2008</b> , 164, 542-6	1
1434	[Therapeutic strategies for the management of gliomas]. <b>2008</b> , 164, 523-30	5
1433	[Neuro-oncology: a shifting speciality]. <b>2008</b> , 164, 501-2	
1432	Adjuvant temozolomide: how long and how much?. <b>2008</b> , 8, 663-5	2

1431	Mechanisms of disease: temozolomide and glioblastoma--look to the future. <b>2008</b> , 5, 476-86	114
1430	Drug cocktails for effective treatment of glioblastoma multiforme. <b>2008</b> , 8, 515-7	17
1429	Brain tumor stem cells: will understanding a new paradigm lead to improved therapies?. <b>2008</b> , 8, 511-4	
1428	Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. <b>2008</b> , 26, 33-44	14
1427	Gadolinium neutron capture in glioblastoma multiforme cells. <b>2008</b> , 84, 1130-9	14
1426	Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. <b>2008</b> , 16, 1783-8	32
1425	Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. <b>2008</b> , 8, 541-53	63
1424	Cintredekin besudotox in treatment of malignant glioma. <b>2008</b> , 8, 805-12	21
1423	Vector therapies for malignant glioma: shifting the clinical paradigm. <b>2008</b> , 5, 445-58	7
1422	Paradoxical expression of anti-apoptotic and MRP genes on cancer stem-like cell isolated from TJ905 glioblastoma multiforme cell line. <b>2008</b> , 26, 338-43	14
1421	Proceedings of the Annual Meeting of the British Neuro-oncology Society (BNOS) to be held at Preston, UK 25-27 June 2008. <b>2008</b> , 22, 332-338	
1420	Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?. <b>2008</b> , 22, 339-49	39
1419	Topoisomerase I inhibitors for the treatment of brain tumors. <b>2008</b> , 8, 707-16	15
1418	Antiangiogenic blockage: a new treatment for glioblastoma. <b>2008</b> , 8, 1449-53	7
1417	Combination therapy for malignant glioma based on PTEN status. <b>2008</b> , 8, 1767-79	10
1416	The role of temozolomide in newly-diagnosed glioblastoma multiforme. <b>2008</b> , 22, 456	
1415	Brain tumors and dementia. <b>2008</b> , 89, 877-86	2
1414	Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. <b>2008</b> , 108, 963-71	148

1413	Modeling and quantifying biochemical changes in C6 tumor gliomas by Fourier transform infrared imaging. <b>2008</b> , 80, 8406-15	38
1412	[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. <b>2008</b> , 164, 588-94	40
1411	Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. <b>2008</b> , 108, 236-42	42
1410	[Current management of brain metastases]. <b>2008</b> , 164, 560-8	7
1409	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. <b>2008</b> , 26, 4189-99	625
1408	In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. <b>2008</b> , 14, 931-8	91
1407	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. <b>2008</b> , 26, 5603-9	218
1406	Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. <b>2008</b> , 10, 617-23	17
1405	Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system. <b>2008</b> , 68, 3396-404	65
1404	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. <b>2008</b> , 10, 330-40	35
1403	Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. <b>2008</b> , 26, 4518-9	23
1402	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. <b>2008</b> , 14, 8205-12	288
1401	Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. <b>2008</b> , 180, 2089-98	89
1400	Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme. <b>2008</b> , 7, 249-55	25
1399	In Wake of Senator Kennedy's Glioma, Neuro-oncologists Weigh in on Treatment Options. <b>2008</b> , 8, 1	
1398	Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. <b>2008</b> , 4, 467-75	109
1397	A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). <b>2008</b> , 38, 715-8	15
1396	Combating immunosuppression in glioma. <b>2008</b> , 4, 433-42	47



1395	The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model. <b>2008</b> , 30, 511-7	15
1394	Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts. <b>2008</b> , 30, 960-7	7
1393	Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. <b>2008</b> , 30, 567-70	21
1392	Extraneural spread of glioblastoma--report of two cases. <b>2008</b> , 31, 192-4	14
1391	Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. <b>2008</b> , 31, 309-13	7
1390	Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. <b>2008</b> , 31, 435-9	5
1389	Management of malignant glioma--quo vadis?. <b>2008</b> , 31, 300-2	6
1388	Concurrent chemoradiotherapy for malignant glioma: dead end or highway?. <b>2008</b> , 31, 430-1	
1387	Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients. <b>2008</b> , 8, 733-41	6
1386	Association between response to primary treatments and MGMT status in glioblastoma. <b>2008</b> , 8, 1781-6	5
1385	Determining glioma response to radiation therapy using recombinant peptides. <b>2008</b> , 8, 1787-96	3
1384	Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. <b>2008</b> , 68, 5778-84	76
1383	Cancer stem cells and survival pathways. <b>2008</b> , 7, 1371-8	94
1382	Translational research in glioblastoma multiforme: molecular criteria for patient selection. <b>2008</b> , 4, 219-28	13
1381	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2008</b> , 19 Suppl 2, ii83-5	13
1380	Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. <b>2008</b> , 4, 525-34	23
1379	EGF receptor variant III as a target antigen for tumor immunotherapy. <b>2008</b> , 7, 977-85	57
1378	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <b>2008</b> , 8, 717-32	8

1377	Pseudoprogression in glioblastoma. <b>2008</b> , 26, 4359; author reply 4359-60	44
1376	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. <b>2008</b> , 10, 98-103	98
1375	Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. <b>2008</b> , 26, 5957-64	58
1374	Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. <b>2008</b> , 19 Suppl 7, vii209-16	26
1373	Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. <b>2008</b> , 10, 1004-9	29
1372	Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. <b>2008</b> , 6, 675-84	188
1371	Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment. <b>2008</b> , 7, 364-73	15
1370	Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. <b>2008</b> , 10, 608-16	25
1369	Engineering of clinical glioma treatment: prediction of pro-invasive molecular events in treated gliomas. <b>2008</b> , 222, 1149-60	2
1368	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. <b>2008</b> , 10, 216-22	46
1367	Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. <b>2008</b> , 10, 190-8	18
1366	Diagnostic and therapeutic stratification of childhood brain tumors: implications for translational research. <b>2008</b> , 23, 1179-85	6
1365	3D conformal radiotherapy and cisplatin for recurrent malignant glioma. <b>2008</b> , 35, 57-64	15
1364	Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. <b>2008</b> , 14, 3098-104	204
1363	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. <b>2008</b> , 10, 300-8	68
1362	Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas. <b>2008</b> , 71, 365-73	23
1361	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. <b>2008</b> , 26, 5610-7	384
1360	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. <b>2008</b> , 26, 2192-7	641

1359	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. <b>2008</b> , 10, 361-7	188
1358	Molecular predictors in glioblastoma: toward personalized therapy. <b>2008</b> , 65, 877-83	57
1357	A pilot study: 131I-antitennascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. <b>2008</b> , 10, 182-9	79
1356	Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. <b>2008</b> , 68, 5267-72	33
1355	Pten haploinsufficiency accelerates formation of high-grade astrocytomas. <b>2008</b> , 68, 3286-94	209
1354	Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. <b>2008</b> , 14, 130-8	209
1353	Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. <b>2008</b> , 10, 995-1003	29
1352	Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme. <b>2008</b> , 7, 241-8	12
1351	Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitennascin monoclonal antibody 81C6. <b>2008</b> , 49, 30-8	272
1350	Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. <b>2008</b> , 10, 1025-34	250
1349	A novel tool to analyze MRI recurrence patterns in glioblastoma. <b>2008</b> , 10, 1019-24	63
1348	From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. <b>2008</b> , 26, 4519-20	40
1347	Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. <b>2008</b> , 13, 978-92	38
1346	Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. <b>2008</b> , 28, 1882-93	77
1345	Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. <b>2008</b> , 68, 6171-80	24
1344	Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. <b>2008</b> , 109, 268-72	71
1343	Radioimmunotherapie maligner Gliome. <b>2008</b> , 31, 164-177	
1342	Palliative treatment of poor prognosis patients with malignant gliomas. <b>2008</b> , 8, 125-32	2

1341	Epigenetic markers in human gliomas: prospects for therapeutic intervention. <b>2008</b> , 8, 1475-96	4
1340	Applications of emerging molecular technologies in glioblastoma multiforme. <b>2008</b> , 8, 1497-506	20
1339	Being old is no fun: treatment of glioblastoma multiforme in the elderly. <b>2008</b> , 108, 639-40	5
1338	Procarbazine--a traditional drug in the treatment of malignant gliomas. <b>2008</b> , 15, 1376-87	10
1337	A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. <b>2008</b> , 10, 569-76	25
1336	Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliSite Radiation Therapy System. <b>2008</b> , 35, 3383-8	13
1335	Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. <b>2008</b> , 10, 79-87	136
1334	Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. <b>2008</b> , 108, 979-88	28
1333	The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. <b>2008</b> , 3, 265-273	5
1332	Temozolomide preferentially depletes cancer stem cells in glioblastoma. <b>2008</b> , 68, 5706-15	236
1331	Cannabinoids as potential new therapy for the treatment of gliomas. <b>2008</b> , 8, 37-49	26
1330	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <b>2008</b> , 17, 1225-35	152
1329	Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. <b>2008</b> , 19, 690-8	71
1328	Anaplastic astrocytomas: biology and treatment. <b>2008</b> , 8, 575-86	8
1327	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. <b>2008</b> , 26, 3015-24	541
1326	Intracavitary radioimmunotherapy to treat solid tumors. <b>2008</b> , 23, 92-107	20
1325	Emerging drugs for malignant glioma. <b>2008</b> , 13, 81-94	15
1324	Gliomes de grade II. <b>2008</b> , 5, 1-17	1

1323	Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. <b>2008</b> , 1, 3-13	2
1322	Chemotherapeutic wafers for High Grade Glioma. <b>2008</b> , CD007294	23
1321	Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. <b>2008</b> ,	
1320	Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. <b>2008</b> ,	1
1319	Temozolomide for high grade glioma. <b>2008</b> , CD007415	35
1318	Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. <b>2008</b> , 1, 863-7	16
1317	MGMT immunohistochemical expression and promoter methylation in human glioblastoma. <b>2008</b> , 16, 59-65	92
1316	Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. <b>2008</b> , 67, 1-15	70
1315	Different Treatment Strategies for Pediatric Brain Tumors. <b>2008</b> , 4, 178-186	
1314	Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. <b>2008</b> , 21, 736-44	45
1313	The Biology of Brain Tumors. <b>2008</b> , 21, 7-9	
1312	Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. <b>2008</b> , 3, 198-203	52
1311	Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. <b>2008</b> , 3, 2-9	20
1310	Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. <b>2008</b> , 19, 613-20	53
1309	Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. <b>2008</b> , 15, 38-46	52
1308	Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. <b>2008</b> , 63, 286-91; discussion 291	95
1307	Cancer stem cells in brain tumor biology. <b>2008</b> , 73, 411-20	61
1306	Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. <b>2008</b> , 21, 745-53	41

1305	Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. <b>2008</b> , 18, 147-51	35
1304	What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?. <b>2008</b> , 21, 717-9	11
1303	Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts. <b>2008</b> , 19, 991-8	10
1302	In Reply. <b>2008</b> , 26, 4359-4360	19
1301	A specialist nurse as a resource for family members to patients with brain tumors: an action research study. <b>2008</b> , 31, E18-26	16
1300	Repeated Implantation of Interstitial Chemotherapy to Treat Malignant Gliomas. <b>2008</b> , 18, 286-289	1
1299	Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. <b>2008</b> , 62, 211-21; discussion 221-2	134
1298	Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. <b>2008</b> , 62, 564-76; discussion 564-76	802
1297	Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. <b>2008</b> , 63, 700-7; author reply 707-8	396
1296	Antiangiogenic therapy in malignant gliomas. <b>2008</b> , 20, 652-61	38
1295	Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. <b>2008</b> , 31, 300-5	77
1294	Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. <b>2008</b> , 14, 279-85	51
1293	Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. <b>2008</b> , 14, 352-7	66
1292	European Organization for Research and Treatment of Cancer (EORTC). <b>2008</b> , 1	
1291	Galectins in Malignant Gliomas: Expression, Functions, and Possible Therapeutic Options. 223-234	
1290	. <b>2008</b> ,	20
1289	Central nervous system. 370-381	
1288	17 Systemic Chemotherapy. <b>2008</b> ,	

1287	TMZ-BioShuttle--a reformulated temozolomide. <b>2008</b> , 5, 273-84	15
1286	Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. <b>2008</b> , 94, 674-680	1
1285	A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma. <b>2008</b> , 2, 455-9	
1284	Current available therapies and future directions in the treatment of malignant gliomas. <b>2008</b> , 15	
1283	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-a critical review. <b>2008</b> , 2, 421-2	37
1282	Therapeutic vaccines for malignant brain tumors. <b>2008</b> , 2, 753-61	5
1281	Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation. <b>2008</b> , 3, e2164	17
1280	Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. <b>2008</b> , 2008, 942618	3
1279	Intraoperative navigation and fluorescence imagings in malignant glioma surgery. <b>2008</b> , 57, 155-61	12
1278	The harm-benefit tradeoff in "bad deal" trials. <b>2007</b> , 17, 321-50	14
1277	Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. <b>2008</b> , 44, ix-xiv	34
1276	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. <b>2009</b> , Volume 1, 137-150	2
1275	Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. <b>2010</b> , 4, 93-111	19
1274	Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride]. <b>2009</b> , 2, 417-21	2
1273	[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas]. <b>2009</b> , 96, 291-7	
1272	Outcome of Newly Diagnosed Glioblastoma Patients Treated by Radiotherapy plus Concomitant and Adjuvant Temozolomide: A Long-Term Analysis. <b>2009</b> , 95, 191-197	42
1271	[Prescription guidebook for temozolomide usage in brain tumors]. <b>2009</b> , 96, 579-89	0
1270	Molecularly targeted therapies for malignant gliomas. <b>2009</b> , 15, 115-22	25

1269	[Prognostic and predictive factors for gliomas in adults]. <b>2009</b> , 96, 357-67	7
1268	Advanced imaging techniques in brain tumors. <b>2009</b> , 9 Spec No A, S4-9	33
1267	Three-Dimensional Conformal Radiotherapy, Temozolomide Chemotherapy, and High-Dose Fractionated Stereotactic Boost in a Protocol-Driven, Postoperative Treatment Schedule for High-Grade Gliomas. <b>2009</b> , 95, 329-337	7
1266	Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. <b>2009</b> , 4, e5209	88
1265	Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. <b>2009</b> , 4, e5947	81
1264	Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. <b>2009</b> , 4, e8536	23
1263	Fluorodeoxyuridine mediated cell cycle synchronization in S-phase increases the Auger radiation cell killing with 125I-iododeoxyuridine. <b>2009</b> , 48, 233-42	4
1262	Temozolomide with radiation therapy in high grade brain gliomas: pharmaceutical considerations and efficacy; a review article. <b>2009</b> , 14, 1561-77	49
1261	Succor or suckers? Benefit, risk, and the therapeutic misconception. 72-88	
1260	Localized BCNU chemotherapy and the multimodal management of malignant glioma. <b>2009</b> , 25, 149-60	40
1259	The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. <b>2009</b> , 8, 3274-84	613
1258	Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. <b>2009</b> , 69, 4502-9	120
1257	Oligodendrogliomas: molecular biology and treatment. <b>2009</b> , 14, 155-63	59
1256	Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. <b>2009</b> , 27, 2052-8	277
1255	Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. <b>2009</b> , 69, 1587-95	81
1254	MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. <b>2009</b> , 15, 4622-9	291
1253	The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. <b>2009</b> , 11, 22-32	10
1252	Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. <b>2009</b> , 11, 825-32	55



1251	Targeting multiple kinases in glioblastoma multiforme. <b>2009</b> , 18, 277-92	36
1250	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. <b>2009</b> , 9, 235-41	16
1249	Design and application of oncolytic HSV vectors for glioblastoma therapy. <b>2009</b> , 9, 505-17	38
1248	Advances in the genetics of glioblastoma: are we reaching critical mass?. <b>2009</b> , 5, 419-26	99
1247	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <b>2009</b> , 8, 2773-9	209
1246	Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. <b>2009</b> , 15, 6551-9	91
1245	FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. <b>2009</b> , 14, 1131-8	432
1244	Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. <b>2009</b> , 27, 4733-40	1864
1243	Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. <b>2009</b> , 15, 887-97	95
1242	Gadolinium dose enhancement studies in microbeam radiation therapy. <b>2009</b> , 36, 3568-74	41
1241	The angiotensin 1/angiotensin 2 balance as a prognostic marker in primary glioblastoma multiforme. <b>2009</b> , 110, 147-55	45
1240	A microarray-based DNA methylation study of glioblastoma multiforme. <b>2009</b> , 4, 255-64	146
1239	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. <b>2009</b> , 27, 579-84	293
1238	Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. <b>2009</b> , 11, 183-91	88
1237	Nimotuzumab in pediatric glioma. <b>2009</b> , 5, 1349-61	19
1236	Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme. <b>2009</b> , 9, 1643-50	12
1235	Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. <b>2009</b> , 100, 1154-64	60
1234	Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. <b>2009</b> , 101, 615-20	38

1233	Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. <b>2009</b> , 101, 1995-2004	106
1232	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <b>2009</b> , 10, 2171-80	11
1231	De novo induction of genetically engineered brain tumors in mice using plasmid DNA. <b>2009</b> , 69, 431-9	103
1230	Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. <b>2009</b> , 15, 7124-9	28
1229	Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. <b>2009</b> , 55, 145-54	2
1228	Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioblastoma. <b>2009</b> , 5 Suppl 1, S44-7	24
1227	Experience with irinotecan for the treatment of malignant glioma. <b>2009</b> , 11, 80-91	119
1226	Improving cancer outcomes through international collaboration in academic cancer treatment trials. <b>2009</b> , 27, 5109-14	42
1225	Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. <b>2009</b> , 27, 5861-2	42
1224	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. <b>2009</b> , 11, 167-75	50
1223	SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. <b>2009</b> , 15, 6609-18	17
1222	Survival of high grade glioma patients depends on their age at diagnosis. <b>2009</b> , 8, 1719-21	16
1221	Bevacizumab for recurrent ependymoma. <b>2009</b> , 73, 1677-80	49
1220	Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. <b>2009</b> , 11, 833-41	64
1219	Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. <b>2009</b> , 7, 1000-12	93
1218	O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. <b>2009</b> , 15, 338-45	303
1217	MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. <b>2009</b> , 27, 5881-6	203
1216	Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. <b>2009</b> , 15, 6683-93	158

1215	Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. <b>2009</b> , 8, 3276-84	46
1214	Primary diffuse leptomeningeal gliomatosis. <b>2009</b> , 62, 16-22	16
1213	Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. <b>2009</b> , 69, 458-65	102
1212	Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. <b>2009</b> , 8, 1739-50	77
1211	Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. <b>2009</b> , 8, 2243-54	92
1210	Management of temozolomide toxicity by nurse practitioners in neuro-oncology. <b>2009</b> , 36, 225-31	4
1209	Head's up on the treatment of malignant glioma patients. <b>2009</b> , 36, E232-40	9
1208	Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. <b>2009</b> , 27, 4155-61	120
1207	Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. <b>2009</b> , 73, 1200-6	253
1206	Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. <b>2009</b> , 11, 109-21	89
1205	Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. <b>2009</b> , 11, 842-52	81
1204	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. <b>2009</b> , 11, 737-46	62
1203	Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?. <b>2009</b> , 30, 681-8	96
1202	The impact of the DNA-repair gene MGMT in malignant gliomas. <b>2009</b> , 32, 30-1	
1201	Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. <b>2009</b> , 76, 184-9	15
1200	Elderly patients with glioblastoma multiforme--an underestimated subpopulation?. <b>2009</b> , 33, 23-4	4
1199	Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. <b>2009</b> , 90, 67-72	25
1198	Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature. <b>2009</b> , 2, 103-110	6

1197	Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. <b>2009</b> , 22, 773-9	12
1196	EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antiprogenic therapy. <b>2009</b> , 2, ra82	225
1195	Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. <b>2009</b> , 69, 8932-40	184
1194	The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. <b>2009</b> , 15, 7092-8	139
1193	Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. <b>2009</b> , 8, 443-53	65
1192	RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas. <b>2009</b> , 8, 1024-6	2
1191	The prognostic role of Beclin 1 protein expression in high-grade gliomas. <b>2009</b> , 5, 930-6	118
1190	Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. <b>2009</b> , 27, E8	55
1189	Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines. <b>2009</b> , 21, 338-46	9
1188	Expression of the reporter genes lacZ and EGFP in human glioblastoma cells using Listeria monocytogenes as vector for gene transfer. <b>2009</b> , 31, 859-68	
1187	Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. <b>2009</b> , 64, E1206; author reply E1206	6
1186	Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. <b>2009</b> , 8, 1924-33	16
1185	The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. <b>2009</b> , 9, 703-15	34
1184	A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. <b>2009</b> , 9, 732-9	13
1183	Changing the clinical picture of challenging tumors: tales becoming reality?. <b>2009</b> , 5, 785-802	1
1182	Exophytic giant cell glioblastoma of the medulla oblongata. <b>2009</b> , 110, 589-93	19
1181	Dronedarone for atrial fibrillation--an odyssey. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1811-3	59.2 59
1180	Self-help activities of brain tumour patients and their relatives. <b>2009</b> , 70, 21-6	4

1179	Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. <b>2009</b> , 250, 887-96	76
1178	New developments in targeted molecular therapies for glioblastoma. <b>2009</b> , 9, 7-10	7
1177	Treatment options for recurrent glioblastoma: pitfalls and future trends. <b>2009</b> , 9, 613-9	29
1176	Unmet needs in the treatment of glioblastoma. <b>2009</b> , 9, 545-51	3
1175	The PEPVIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <b>2009</b> , 9, 1087-98	67
1174	Bevacizumab in brain tumors: ready for primetime?. <b>2009</b> , 5, 1183-4	5
1173	Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. <b>2009</b> , 18, 1549-57	43
1172	Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. <b>2009</b> , 110, 173-80	206
1171	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. <b>2009</b> , 72, 1217-22	201
1170	Hypoxia helps glioma to fight therapy. <b>2009</b> , 9, 381-90	86
1169	Biological equivalent dose studies for dose escalation in the stereotactic synchrotron radiation therapy clinical trials. <b>2009</b> , 36, 725-33	21
1168	Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas. <b>2009</b> , 50, 2025-32	13
1167	Current concepts and newer developments in the treatment of malignant gliomas. <b>2009</b> , 46, 88-95	13
1166	Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. <b>2009</b> , 46, 96-107	10
1165	Therapy for glioma: Indian perspective. <b>2009</b> , 46, 127-31	5
1164	Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. <b>2009</b> , 11, 430-6	47
1163	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. <b>2009</b> , 20, 182-7	42
1162	A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. <b>2009</b> , 20, 175-81	90

1161	Medical decision-making capacity in patients with malignant glioma. <b>2009</b> , 73, 2086-92	85
1160	Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. <b>2009</b> , 11, 142-50	29
1159	Oncogenic EGFR signaling networks in glioma. <b>2009</b> , 2, re6	239
1158	A pragmatic clinicopathobiological grouping/staging system for gliomas: proposal of the Indian TNM subcommittee on brain tumors. <b>2009</b> , 57, 247-51	1
1157	Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. <b>2009</b> , 69, 2540-9	101
1156	High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. <b>2009</b> , 2009, 531692	20
1155	Curability of cancer by radiotherapy and chemotherapy, including in neuraxial neoplasms. <b>2009</b> , 57, 13-9	2
1154	DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. <b>2009</b> , 11, 529-42	79
1153	Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. <b>2009</b> , 11, 437-45	124
1152	Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. <b>2009</b> , 17, 199-207	278
1151	Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. <b>2009</b> , 69, 9133-40	161
1150	Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. <b>2009</b> , 11, 357-67	46
1149	Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. <b>2009</b> , 5 Suppl 1, S7-15	35
1148	Tumor-associated epilepsy and glioma: are there common genetic pathways?. <b>2009</b> , 48, 955-63	40
1147	The role of surgery in the management of intracranial gliomas: current concepts. <b>2009</b> , 46, 120-6	7
1146	Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. <b>2009</b> , 48, 52-8	86
1145	Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <b>2009</b> , 11, 747-56	68
1144	Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. <b>2009</b> , 11, 803-18	32

1143	Independent association of extent of resection with survival in patients with malignant brain astrocytoma. <b>2009</b> , 110, 156-62	573
1142	Equal care for the elderly with low-grade gliomas?. <b>2009</b> , 73, 2056-7	1
1141	Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. <b>2009</b> , 8, 394-406	104
1140	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. <b>2009</b> , 8, 3285-95	30
1139	Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. <b>2009</b> , 27, 5781-7	19
1138	Boron neutron capture therapy for newly diagnosed glioblastoma. <b>2009</b> , 50, 51-60	94
1137	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. <b>2009</b> , 11, 281-91	212
1136	The Pyk2 FERM domain as a target to inhibit glioma migration. <b>2009</b> , 8, 1505-14	26
1135	Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. <b>2009</b> , 27, 3861-7	137
1134	Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. <b>2009</b> , 27, 740-5	1228
1133	Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. <b>2009</b> , 15, 3850-5	22
1132	New (alternative) temozolomide regimens for the treatment of glioma. <b>2009</b> , 11, 69-79	125
1131	Hypersensitivity pneumonitis associated with the use of temozolomide. <b>2009</b> , 33, 931-4	12
1130	Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. <b>2009</b> , 110, 583-8	223
1129	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. <b>2009</b> , 8, 407-14	75
1128	In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. <b>2009</b> , 15, 607-12	133
1127	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. <b>2009</b> , 27, 1268-74	429
1126	Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. <b>2009</b> , 15, 701-7	56

1125	Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. <b>2009</b> , 106, 10746-51	143
1124	The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. <b>2009</b> , 69, 2809-16	86
1123	Angiogenesis as a therapeutic target in malignant gliomas. <b>2009</b> , 14, 621-36	87
1122	The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. <b>2009</b> , 54, 5525-39	45
1121	Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. <b>2009</b> , 15, 160-8	11
1120	Chemotherapy for malignant gliomas. <b>2009</b> , 19, 150-4	14
1119	Molecular advances of brain tumors in radiation oncology. <b>2009</b> , 19, 171-8	54
1118	Normal tissue tolerance for high-grade gliomas: is it an issue?. <b>2009</b> , 19, 187-92	4
1117	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <b>2009</b> , 9, 101	24
1116	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. <b>2009</b> , 9, 308	61
1115	Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. <b>2009</b> , 9, 372	101
1114	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. <b>2009</b> , 9, 444	143
1113	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. <b>2009</b> , 1286, 13-8	177
1112	High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. <b>2009</b> , 188, 77-82	27
1111	Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. <b>2009</b> , 15, 45-56	507
1110	Neuro-oncology: clinical and molecular predictive factors. <b>2009</b> , 8, 17-9	1
1109	Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. <b>2009</b> , 36, S17-24	16
1108	Statistical and trial design considerations in central nervous system prophylaxis studies. <b>2009</b> , 36, S69-76	5



1107	Molecularly targeted therapies for glioma. <b>2009</b> , 66, 717-29	20
1106	ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. <b>2009</b> , 57, 499-509	41
1105	Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. <b>2009</b> , 57, 1458-67	143
1104	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. <b>2009</b> , 30, E451-9	37
1103	Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. <b>2009</b> , 124, 2505-11	57
1102	IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. <b>2009</b> , 125, 680-7	67
1101	Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. <b>2009</b> , 125, 1222-30	44
1100	Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. <b>2010</b> , 126, 919-29	30
1099	O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?. <b>2009</b> , 115, 1070-80	43
1098	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. <b>2009</b> , 115, 2188-98	64
1097	Chloroquine in glioblastoma--new horizons for an old drug. <b>2009</b> , 115, 2380-3	24
1096	Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. <b>2009</b> , 115, 2964-70	25
1095	Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. <b>2009</b> , 115, 3501-11	109
1094	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. <b>2009</b> , 115, 3512-8	179
1093	Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). <b>2009</b> , 115, 3758-66	90
1092	Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. <b>2009</b> , 115, 4783-94	67
1091	Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation. <b>2009</b> , 115, 4959-72	28
1090	Organotypic glioma spheroids for screening of experimental therapies: how many spheroids and sections are required?. <b>2009</b> , 75, 528-34	14

1089	Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. <b>2009</b> , 39, 1323-33	31
1088	Cancer stem cells: cell culture, markers, and targets for new therapies. <b>2009</b> , 108, 1031-8	146
1087	Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. <b>2009</b> , 48, 908-24	36
1086	A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. <b>2009</b> , 11, 1005-11	19
1085	From birth till death: neurogenesis, cell cycle, and neurodegeneration. <b>2009</b> , 292, 1953-61	19
1084	Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. <b>2009</b> , 168, 705-10	25
1083	Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. <b>2009</b> , 135, 1239-44	29
1082	A comparative study of ectonucleotidase and P2 receptor mRNA profiles in C6 cell line cultures and C6 ex vivo glioma model. <b>2009</b> , 335, 331-40	14
1081	Dendritic-cell- and peptide-based vaccination strategies for glioma. <b>2009</b> , 32, 265-73; discussion 273	31
1080	The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. <b>2009</b> , 14, 299-306	46
1079	Nouvelles thfapeutiques ciblès dans les glioblastomes. <b>2009</b> , 11, 72-77	
1078	Glioblastomes: aspects molçulaires et prise en charge actuelle. <b>2009</b> , 11, 67-71	1
1077	The effects of acetaminophen combined with radiation on the radiosensitivity of irradiated human glioma cell progeny. <b>2009</b> , 8, 203-206	
1076	Biology of glioma cancer stem cells. <b>2009</b> , 28, 7-12	106
1075	Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas. <b>2009</b> , 151, 109-12	6
1074	Multi-photon excitation fluorescence microscopy of brain-tumour tissue and analysis of cell density. <b>2009</b> , 151, 253-62; discussion 262	20
1073	Cerebellar glioblastomas: pathophysiology, clinical presentation and management. <b>2009</b> , 151, 653-7	27
1072	Long-term survivors of glioblastoma: clinical features and molecular analysis. <b>2009</b> , 151, 1349-58	58

1071	Modification of glucose metabolism in radiation-induced brain injury areas using cervical spinal cord stimulation. <b>2009</b> , 151, 1419-25	11
1070	Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. <b>2009</b> , 151, 1377-83	56
1069	The future of neuro-oncology. <b>2009</b> , 151, 1343-8	3
1068	Rechallenge with temozolomide in patients with recurrent gliomas. <b>2009</b> , 256, 734-41	80
1067	Efficacy of anti-epileptic drugs in patients with gliomas and seizures. <b>2009</b> , 256, 1519-26	149
1066	Toward effective immunotherapy for the treatment of malignant brain tumors. <b>2009</b> , 6, 527-38	33
1065	Antiangiogenic strategies for treatment of malignant gliomas. <b>2009</b> , 6, 513-26	30
1064	Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. <b>2009</b> , 30, 2302-18	231
1063	Imaging after GliSite brachytherapy: prognostic MRI indicators of disease control and recurrence. <b>2009</b> , 75, 1385-91	9
1062	Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. <b>2009</b> , 75, 164-9	18
1061	Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. <b>2009</b> , 75, 212-9	73
1060	A novel murine model for localized radiation necrosis and its characterization using advanced magnetic resonance imaging. <b>2009</b> , 75, 527-33	18
1059	Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. <b>2009</b> , 75, 1511-9	50
1058	Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. <b>2009</b> , 91, 95-100	72
1057	A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). <b>2009</b> , 91, 175-82	84
1056	Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. <b>2009</b> , 91, 199-206	98
1055	Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. <b>2009</b> , 91, 213-20	12
1054	Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. <b>2009</b> , 91, 221-5	17

1053	Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. <b>2009</b> , 91, 237-9	12
1052	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. <b>2009</b> , 91, 183-9	62
1051	Modeling the effects of resection, radiation and chemotherapy in glioblastoma. <b>2009</b> , 91, 287-93	12
1050	Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. <b>2009</b> , 91, 329-36	232
1049	Tuberculosis in a patient on temozolomide: a case report. <b>2009</b> , 92, 33-5	7
1048	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. <b>2009</b> , 92, 45-8	36
1047	A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. <b>2009</b> , 92, 79-86	52
1046	A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). <b>2009</b> , 92, 99-105	144
1045	Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. <b>2009</b> , 92, 185-91	118
1044	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. <b>2009</b> , 92, 227-32	15
1043	Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. <b>2009</b> , 93, 229-32	22
1042	Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. <b>2009</b> , 93, 279-83	15
1041	Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. <b>2009</b> , 93, 253-60	10
1040	Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. <b>2009</b> , 93, 191-201	32
1039	High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. <b>2009</b> , 93, 343-8	11
1038	Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. <b>2009</b> , 93, 425-30	13
1037	Cisplatin and BCNU chemotherapy in primary glioblastoma patients. <b>2009</b> , 94, 57-62	17
1036	Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?. <b>2009</b> , 94, 145-8	5

1035	Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. <b>2009</b> , 94, 97-101	95
1034	No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. <b>2009</b> , 94, 169-72	13
1033	Management of newly diagnosed glioblastoma: guidelines development, value and application. <b>2009</b> , 93, 1-23	39
1032	Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. <b>2009</b> , 93, 25-39	89
1031	Aggression in a patient with primary brain tumor: ethical implications for best management. <b>2009</b> , 94, 293-6	10
1030	Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. <b>2009</b> , 94, 203-12	52
1029	Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. <b>2009</b> , 94, 409-18	63
1028	Disseminated strongyloidiasis complicating glioblastoma therapy: a case report. <b>2009</b> , 94, 439-43	15
1027	Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. <b>2009</b> , 94, 445-8	17
1026	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. <b>2009</b> , 95, 61-64	20
1025	Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse. <b>2009</b> , 95, 23-28	7
1024	Differentiation of SWO-38 glioma cells induced by CDA-2 is mediated by peroxisome proliferator-activated receptor gamma. <b>2009</b> , 95, 29-36	9
1023	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. <b>2009</b> , 95, 129-134	38
1022	Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. <b>2009</b> , 95, 151-163	38
1021	Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. <b>2009</b> , 95, 185-197	39
1020	Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. <b>2009</b> , 95, 247-257	34
1019	Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. <b>2009</b> , 95, 199-209	63
1018	Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. <b>2009</b> , 95, 307-316	17

1017	Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. <b>2009</b> , 95, 331-342	28
1016	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <b>2009</b> , 95, 393-400	37
1015	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. <b>2009</b> , 95, 401-411	136
1014	Neurological outcome of long-term glioblastoma survivors. <b>2009</b> , 95, 301-305	52
1013	Local controlled delivery of anti-neoplastic RNase to the brain. <b>2009</b> , 26, 1838-46	11
1012	Brazilian marine sponge <i>Polymastia janeirensis</i> induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture. <b>2009</b> , 27, 13-20	21
1011	Glioblastoma multiforme. <b>2009</b> , 11, 297-305	2
1010	Neuro-oncology of Neurofibromatosis Type 1. <b>2009</b> , 11, 306-14	10
1009	Treatment of spinal cord tumors. <b>2009</b> , 11, 315-24	9
1008	Low-grade gliomas. <b>2009</b> , 10, 231-42	32
1007	Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. <b>2009</b> , 9, 241-6	126
1006	Anti-vascular endothelial growth factor therapy for malignant glioma. <b>2009</b> , 9, 254-62	13
1005	Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions. <b>2009</b> , 11, 62-7	9
1004	Rebestrahlung von Gliomrezidiven mit modernen Techniken in der Radioonkologie. <b>2009</b> , 2, 30-37	
1003	Herausforderungen in der Diagnose und Behandlung von Rezidivgliomen. <b>2009</b> , 2, 23-29	1
1002	Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. <b>2009</b> , 45, 500-11	13
1001	Glioblastome. <b>2009</b> , 4, 4-11	1
1000	Temozolomide [what regimen in what situation?]. <b>2009</b> , 2, 8-9	

999	Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. <b>2009</b> , 185, 524-9	19
998	Radiation therapy for prevention of heterotopic ossification about the elbow. <b>2009</b> , 185, 506-11	22
997	Hypofractionated reirradiation for recurrent malignant glioma. <b>2009</b> , 185, 113-9	58
996	The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models. <b>2009</b> , 185, 743-50	30
995	Tumor initiating cells in malignant gliomas: biology and implications for therapy. <b>2009</b> , 87, 363-74	67
994	Brain cancer stem cells. <b>2009</b> , 87, 1087-95	50
993	Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. <b>2009</b> , 36, 94-103	37
992	Topotecan enhances immune clearance of gliomas. <b>2009</b> , 58, 259-70	17
991	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. <b>2009</b> , 58, 1627-34	174
990	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <b>2009</b> , 64, 769-75	75
989	Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. <b>2009</b> , 64, 171-5	4
988	Temozolomide in malignant gliomas: current use and future targets. <b>2009</b> , 64, 647-55	135
987	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. <b>2009</b> , 64, 863-6	7
986	Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. <b>2009</b> , 27, 2320-30	146
985	Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. <b>2009</b> , 27, 980-7	178
984	NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. <b>2010</b> , 28, 5-16	473
983	Notch promotes radioresistance of glioma stem cells. <b>2010</b> , 28, 17-28	415
982	DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. <b>2009</b> , 27, 1473-86	72

981	Radiation-induced gliomas. <b>2009</b> , 9, 1511-7	64
980	Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?. <b>2009</b> , 52, 796-803	16
979	Non-Hodgkin lymphoma following temozolomide. <b>2009</b> , 53, 661-2	12
978	Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. <b>2009</b> , 53, 1029-34	139
977	Proteomic expression analysis and comparison of protein and mRNA expression profiles in human malignant gliomas. <b>2009</b> , 3, 83-94	10
976	Short-term effects of synchrotron irradiation on vasculature and tissue in healthy mouse brain. <b>2009</b> , 16, 477-83	6
975	Stereotactic radiosurgery for glioblastoma: retrospective analysis. <b>2009</b> , 4, 11	58
974	Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. <b>2009</b> , 4, 43	134
973	Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison. <b>2009</b> , 4, 57	53
972	Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). <b>2009</b> , 9, 1	140
971	Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. <b>2009</b> , 35, 208-13	25
970	Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. <b>2009</b> , 100, 165-72	23
969	Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. <b>2009</b> , 100, 1870-9	30
968	A color-coded orthotopic nude-mouse treatment model of brain-metastatic paralyzing spinal cord cancer that induces angiogenesis and neurogenesis. <b>2009</b> , 42, 75-82	18
967	Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. <b>2009</b> , 16, 1465-76	21
966	Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. <b>2009</b> , 16, 256-65	38
965	A coculture assay to visualize and monitor interactions between migrating glioma cells and nerve fibers. <b>2009</b> , 4, 923-7	12
964	New advances that enable identification of glioblastoma recurrence. <b>2009</b> , 6, 648-57	114



963	Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. <b>2009</b> , 28, 2266-75	152
962	Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. <b>2009</b> , 101, 124-31	236
961	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. <b>2009</b> , 101, 1986-94	167
960	Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. <b>2010</b> , 122, 58-62	34
959	Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas. <b>2009</b> , 276, 7291-304	30
958	Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. <b>2009</b> , 29, 379-88	29
957	Genetically engineered mouse models of brain cancer and the promise of preclinical testing. <b>2009</b> , 19, 132-43	118
956	Immunotherapy of diffuse gliomas: biological background, current status and future developments. <b>2009</b> , 19, 674-93	73
955	Dendritic cell therapy of high-grade gliomas. <b>2009</b> , 19, 694-712	74
954	Immunotherapy of diffuse gliomas: helping the brain fight back!. <b>2009</b> , 19, 672-3	0
953	EGFRvIII-targeted vaccination therapy of malignant glioma. <b>2009</b> , 19, 713-23	107
952	Down-regulation of lipocalin 2 contributes to chemoresistance in glioblastoma cells. <b>2009</b> , 111, 1238-51	25
951	A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. <b>2009</b> , 73, 222-7	44
950	Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. <b>2009</b> , 73, 473-8	53
949	Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. <b>2009</b> , 73, 479-85	119
948	Prognosis and treatment of spinal cord astrocytoma. <b>2009</b> , 73, 727-33	122
947	Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. <b>2009</b> , 73, 699-708	73
946	Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features. <b>2009</b> , 205, 765-73	19

945	Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. <b>2009</b> , 21, 19-22	9
944	Management of glioblastoma multiforme in HIV patients: a case series and review of published studies. <b>2009</b> , 21, 591-7	20
943	Combined radio- and chemotherapy of brain tumours in adult patients. <b>2009</b> , 21, 515-24	27
942	Current practices and future directions of therapeutic strategy in glioblastoma: survival benefit and indication of BNCT. <b>2009</b> , 67, S12-4	5
941	Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. <b>2009</b> , 67, S22-4	15
940	Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. <b>2009</b> , 30, 52-7	265
939	Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. <b>2009</b> , 69, 199-210	23
938	Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development. <b>2009</b> , 70, 206-15	4
937	Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. <b>2009</b> , 74, 433-9	72
936	Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. <b>2009</b> , 75, 810-6	15
935	On the path to seeking novel radiosensitizers. <b>2009</b> , 73, 988-96	33
934	Twenty-year survival in glioblastoma: a case report and molecular profile. <b>2009</b> , 75, 1162-5	18
933	Rad51 protein expression and survival in patients with glioblastoma multiforme. <b>2009</b> , 74, 1251-5	35
932	Boron neutron capture therapy at the crossroads: challenges and opportunities. <b>2009</b> , 67, S3-6	94
931	Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. <b>2009</b> , 34, 3-35	58
930	Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. <b>2009</b> , 15, 6871-80	99
929	Applications of neural and mesenchymal stem cells in the treatment of gliomas. <b>2009</b> , 9, 597-612	64
928	Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. <b>2009</b> , 8, 452-7	23

927	Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. <b>2009</b> , 111, 219-25	43
926	EZH2 is essential for glioblastoma cancer stem cell maintenance. <b>2009</b> , 69, 9211-8	371
925	High-grade glioma mouse models and their applicability for preclinical testing. <b>2009</b> , 35, 714-23	49
924	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. <b>2009</b> , 45, 146-53	44
923	PDGFR inhibition in brain tumours--oft expectation fails where most it promises. <b>2009</b> , 45, 2236-8	6
922	Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. <b>2009</b> , 45, 3315-25	37
921	Anesthetic pentobarbital inhibits proliferation and migration of malignant glioma cells. <b>2009</b> , 282, 35-42	15
920	Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. <b>2009</b> , 284, 71-9	40
919	[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma]. <b>2009</b> , 13, 17-23	7
918	Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?. <b>2009</b> , 111, 331-4	51
917	Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: single-center experience. <b>2009</b> , 111, 679-82	36
916	Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. <b>2009</b> , 111, 748-51	15
915	Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. <b>2009</b> , 379, 434-9	27
914	Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. <b>2009</b> , 380, 236-42	113
913	DNA ligase IV as a new molecular target for temozolomide. <b>2009</b> , 387, 656-60	20
912	Primary diffuse leptomenigeal gliomatosis in a 2-year-old girl. <b>2009</b> , 71, 713-9, discussion 719	5
911	Commentary. <b>2009</b> , 71, 719	
910	Association of preoperative depression and survival after resection of malignant brain astrocytoma. <b>2009</b> , 71, 299-303, discussion 303	56

909 Commentary. **2009**, 71, 303

908 Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. **2009**, 72, 423-8 98

907 Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. **2009**, 32, 559-65 26

906 Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. **2009**, 30, 303-12 533

905 L'hyperméthylation des gènes suppresseurs de tumeur comme marqueur en cancérologie. **2009**, 24, 9-15

904 Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. **2009**, 16, 591-2 13

903 Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?. **2009**, 16, 854-5 28

902 Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre. **2009**, 16, 1174-9 10

901 Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. **2009**, 16, 1119-30 80

900 Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China. **2009**, 16, 1595-8 47

899 Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3beta androstene 17alpha diol neuro-steroid on malignant glioma cells. **2009**, 115, 137-45 21

898 New drugs for brain tumors? Insights from chemical probing of neural stem cells. **2009**, 72, 683-7 24

897 Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. **2009**, 7, 489-97 205

896 The optimization of fluorescence imaging of brain tumor tissue differentiated from brain edema—in vivo kinetic study of 5-aminolevulinic acid and talaporfin sodium. **2009**, 6, 19-27 17

895 Expression and hypoxic up-regulation of neuroglobin in human glioblastoma cells. **2009**, 3, 45-53 31

894 Late effects of CNS radiation therapy. **2009**, 150, 23-41 12

893 Quantitative imaging biomarkers in neuro-oncology. **2009**, 6, 445-54 79

892 Therapeutic strategies for inhibiting invasion in glioblastoma. **2009**, 9, 519-34 60

891	p53 mutant human glioma cells are sensitive to UV-C-induced apoptosis due to impaired cyclobutane pyrimidine dimer removal. <b>2009</b> , 7, 237-46	24
890	Antiangiogenic therapies for high-grade glioma. <b>2009</b> , 5, 610-20	204
889	Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. <b>2009</b> , 8, 66	69
888	Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. <b>2009</b> , 7, 13	44
887	Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. <b>2009</b> , 7, 77	61
886	Immunological considerations of modern animal models of malignant primary brain tumors. <b>2009</b> , 7, 84	18
885	Chapter 11 - Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges. <b>2009</b> , 180, 193-223	10
884	IDH1 and IDH2 mutations in gliomas. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 765-73	59.2 4220
883	Glioblastoma multiforme: a review of where we have been and where we are going. <b>2009</b> , 18, 1061-83	358
882	Proteomic and immunologic analyses of brain tumor exosomes. <b>2009</b> , 23, 1541-57	315
881	Glioblastoma multiforme: a review of therapeutic targets. <b>2009</b> , 13, 701-18	119
880	Radiation-induced gliomas. <b>2009</b> , 9, 1511-1517	42
879	Pediatric gliomas. <b>2009</b> , 171, 67-81	30
878	Gliomas. <b>2009</b> ,	11
877	Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. <b>2009</b> , 13, 455-68	67
876	Targeted drug delivery for treatment and imaging of glioblastoma multiforme. <b>2009</b> , 6, 705-18	18
875	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <b>2009</b> , 27, 5874-80	625
874	Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. <b>2009</b> , 24, 1409-17	66

873	New strategies to deliver anticancer drugs to brain tumors. <b>2009</b> , 6, 1017-32	148
872	Low-grade oligodendroglioma: current treatments and future hopes. <b>2009</b> , 9, 1651-61	7
871	Intérêt de l'association bvacizumab/irinotécan dans le traitement des glioblastomes. Une étude multicentrique de l'ANOCEF. <b>2009</b> , 165, S16-S18	
870	In vitro and in vivo optimization of an anti-glioma modality based on synchrotron X-ray photoactivation of platinated drugs. <b>2009</b> , 172, 348-58	13
869	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2009</b> , 20 Suppl 4, 126-8	83
868	Convection-enhanced delivery for the treatment of brain tumors. <b>2009</b> , 9, 1519-27	138
867	The safety of temozolomide in the treatment of malignancies. <b>2009</b> , 8, 493-9	51
866	Age as a predictive factor in glioblastomas: population-based study. <b>2009</b> , 33, 17-22	92
865	Insights into pharmacotherapy of malignant glioma in adults. <b>2009</b> , 10, 2279-90	4
864	Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. <b>2009</b> , 85, 126-37	67
863	Targeted therapies for malignant glioma: progress and potential. <b>2009</b> , 23, 25-35	36
862	Analyzing the diffusion patterns for follow-up study of Glioblastoma multiforme using Diffusion Tensor Imaging. <b>2009</b> ,	0
861	Health-related quality of life of long-term high-grade glioma survivors. <b>2009</b> , 11, 51-8	59
860	Insights into gliomagenesis: systems biology unravels key pathways. <b>2009</b> , 1, 101	1
859	Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. <b>2009</b> , 23, 351-63	40
858	Infrared thermal imaging: a review of the literature and case report. <b>2009</b> , 47 Suppl 2, T154-62	90
857	Boron neutron capture therapy for newly diagnosed glioblastoma. <b>2009</b> , 91, 80-4	57
856	Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. <b>2009</b> , 91, 60-6	15

855	Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile?. <b>2009</b> , 120, 288-94	39
854	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <b>2009</b> , 10, 459-66	5111
853	A silver lining on the horizon for glioblastoma. <b>2009</b> , 10, 434-5	18
852	Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): a retrospective cohort study. <b>2009</b> , 53, 318-24	5
851	A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. <b>2009</b> , 9, 1565-75	24
850	Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. <b>2009</b> , 27, 1257-61	108
849	Emerging subspecialties in neurology: neuro-oncology: a developing subspecialty with many opportunities. <b>2009</b> , 72, e51-3	3
848	Gene Therapy for Brain Tumors. <b>2009</b> , 3083-3116	
847	Therapeutic advances in malignant glioma: current status and future prospects. <b>2009</b> , 19, 647-56	21
846	Modeling Adult Gliomas Using RCAS/t-va Technology. <b>2009</b> , 2, 89-95	181
845	Magnetic resonance perfusion and permeability imaging in brain tumors. <b>2009</b> , 19, 527-57	109
844	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. <b>2009</b> , 27, 5743-50	464
843	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. <b>2009</b> , 27, 1275-9	249
842	Diagnostic and prognostic markers in gliomas. <b>2009</b> , 21, 537-42	38
841	Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. <b>2009</b> , 32, 914-9	76
840	Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. <b>2009</b> , 65, 463-9; discussion 469-70	282
839	Combining drugs and radiotherapy: from the bench to the bedside. <b>2009</b> , 22, 625-32	16
838	Classification and management of anaplastic gliomas. <b>2009</b> , 22, 650-6	10

837	Treatment of recurrent high-grade gliomas. <b>2009</b> , 22, 657-64	22
836	Clinicopathologic Characteristics of Brain Gliomas: Experience From Culturally and Geographically Distinct Kashmir Valley. <b>2009</b> , 19, 288-294	1
835	Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal wistar rats. <b>2009</b> , 65, 344-50; discussion 350-1	24
834	Treatment of glioblastoma in older patients. <b>2009</b> , 5, 113-125	
833	Glioblastoma multiforme in a patient with chronic granulomatous disease treated with subtotal resection, radiation, and thalidomide: case report of a long-term survivor. <b>2009</b> , 31, 965-9	5
832	The clinical experience with particle therapy in adults. <b>2009</b> , 15, 306-11	22
831	The importance of surgical resection in malignant glioma. <b>2009</b> , 22, 645-9	68
830	NCCN task force: clinical utility of PET in a variety of tumor types. <b>2009</b> , 7 Suppl 2, S1-26	76
829	p15 promoter methylation - a novel prognostic marker in glioblastoma patients. <b>2009</b> , 34, 1743-8	18
828	Effect of IFN-beta on human glioma cell lines with temozolomide resistance. <b>2009</b> , 35, 139-48	35
827	Population-based study of pseudoprogression after chemoradiotherapy in GBM. <b>2009</b> , 36, 617-22	56
826	Targeted therapy of glioblastomas: a 5-year view. <b>2009</b> , 6, 351-370	4
825	[Evaluation of stability of temozolomide in solutions after opening the capsule]. <b>2009</b> , 129, 353-7	5
824	A Correction to the Review Titled: "Oncogenic EGFR Signaling Networks in Glioma" by P. H. Huang, A. M. Xu, F. M. White. <b>2009</b> , 2, er7-er7	
823	CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. <b>2009</b> , 21,	3
822	Glioblastoma Multiforme Oncogenomics and Signaling Pathways. <b>2009</b> , 3, 39-52	89
821	Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. <b>2009</b> , 9, 389-95	14
820	Advances in oncolytic virus therapy for glioma. <b>2009</b> , 4, 1-13	47



819	STAT3 regulation of glioblastoma pathogenesis. <b>2009</b> , 9, 580-90	89
818	Seeing genes at work in the living brain with non-invasive molecular imaging. <b>2009</b> , 9, 212-38	15
817	Advances in peptide pharmaceuticals. <b>2009</b> , 10, 122-37	87
816	Aspects għtiques des tumeurs cfbrales primitives de l'adulte. <b>2009</b> , 6, 1-10	
815	Perfusion MRI of Brain Neoplams. <b>2010</b> , 6, 232-245	1
814	Gliomas: Current Issues in Diagnosis and Treatment. <b>2010</b> , 6, 285-294	
813	Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways. <b>2010</b> , 69, 582-92	15
812	Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. <b>2010</b> , 69, 729-36	66
811	The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. <b>2010</b> , 5, 172-87	24
810	Diffusion-weighted MRI for assessment of early cancer treatment response. <b>2010</b> , 11, 701-8	25
809	Abstracts. <b>2010</b> , 23, 75-370	
808	Pseudoprogession following chemoradiotherapy for glioblastoma multiforme. <b>2010</b> , 37, 36-42	89
807	Long-term survival of a patient with glioblastoma. <b>2010</b> , 37, 289-92	2
806	Clinical significance of molecular biomarkers in glioblastoma. <b>2010</b> , 37, 625-30	32
805	Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme. <b>2010</b> , 32, e202-6	5
804	Glioma diagnosis: immunohistochemistry and beyond. <b>2010</b> , 17, 187-201	46
803	Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. <b>2010</b> , 21, 963-7	17
802	Supportive care in neurooncology. <b>2010</b> , 22, 621-6	38

801	Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. <b>2010</b> , 66, 530-7; discussion 537	50
800	Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma. <b>2010</b> , 67, 1386-95; discussion 1395	50
799	Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. <b>2010</b> , 66, 144-56; discussion 156-7	73
798	Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). <b>2010</b> , 67, 446-58	63
797	Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors. <b>2010</b> , 50, 1062-9	16
796	Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. <b>2010</b> , 50, 638-44	22
795	Gene therapy for high-grade glioma. <b>2010</b> , 50, 727-36	14
794	Standard therapy for glioblastoma--a review of where we are. <b>2010</b> , 50, 713-9	46
793	A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. <b>2010</b> , 67, 313-9	47
792	Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells. <b>2010</b> , 26, 713-21	8
791	Pharmacological treatment of depression in patients with a primary brain tumour. <b>2010</b> , CD006932	19
790	Alternative responses of primary tumor cells and glioblastoma cell lines to N,N-bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines: cell death versus P53-independent senescence. <b>2010</b> , 37, 1463-70	4
789	Higher pAkt expression predicts a significant worse prognosis in glioblastomas. <b>2010</b> , 51, 343-8	48
788	Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. <b>2010</b> , 96, 60-64	21
787	Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. <b>2010</b> , 17, 1740-6	60
786	Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. <b>2010</b> , 17, 1729-31	16
785	Chemotherapy: continued lack of progress in SCLC. <b>2010</b> , 7, 77-8	2
784	Malignant gliomas: new translational therapies. <b>2010</b> , 77, 655-66	16

783	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <b>2010</b> , 6, 39-51	538
782	Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. <b>2010</b> , 18, 377-85	72
781	Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. <b>2010</b> , 12, 69-79	22
780	Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. <b>2010</b> , 37, 84-92	77
779	Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. <b>2010</b> , 37, 1335-44	137
778	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. <b>2010</b> , 65, 353-61	143
777	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <b>2010</b> , 65, 391-7	23
776	Targeting O <sup>6</sup> -methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. <b>2010</b> , 67, 3663-81	103
775	Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. <b>2010</b> , 186, 558-64	29
774	Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. <b>2010</b> , 186, 452-7	15
773	[Prediction of clinical course of glioblastomas by MRI during radiotherapy]. <b>2010</b> , 186, 681-6	7
772	[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. <b>2010</b> , 81, 928-30, 932-5	1
771	[Neuroradiological response criteria for malignant gliomas]. <b>2010</b> , 81, 950-5	6
770	Uptake and intracellular release kinetics of liposome formulations in glioma cells. <b>2010</b> , 395, 251-9	39
769	A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. <b>2010</b> , 76, 1177-84	101
768	Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. <b>2010</b> , 77, 670-6	40
767	Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. <b>2010</b> , 78, 1147-55	102
766	A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. <b>2010</b> , 262, 553-65	44

765	Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features. <b>2010</b> , 26, 137-43	7
764	MGMT gene promoter methylation in pediatric glioblastomas. <b>2010</b> , 26, 1613-8	33
763	Molecular diagnostics of gliomas: state of the art. <b>2010</b> , 120, 567-84	208
762	Molecular diagnostics of gliomas: the clinical perspective. <b>2010</b> , 120, 585-92	96
761	Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. <b>2010</b> , 27, 29-34	17
760	p53 abnormality and tumor invasion in patients with malignant astrocytoma. <b>2010</b> , 27, 95-101	19
759	Intratumoral patterns of clonal evolution in gliomas. <b>2010</b> , 11, 227-39	19
758	Controversies concerning the application of brachytherapy in central nervous system tumors. <b>2010</b> , 136, 173-85	21
757	Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme. <b>2010</b> , 136, 1423-9	8
756	Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. <b>2010</b> , 136, 1691-5	40
755	Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. <b>2010</b> , 33, 375-81; discussion 381	8
754	First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. <b>2010</b> , 33, 441-9	90
753	O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. <b>2010</b> , 15, 352-8	50
752	Mise au point sur la pseudoprogression après chimioradiothérapie dans les glioblastomes. <b>2010</b> , 12, 559-564	1
751	Clinical observation in three-dimensional conformal radiotherapy (3D-CRT) with concurrent chemotherapy in treatment of postoperative cerebral gliomas. <b>2010</b> , 9, 193-197	1
750	Conventional radiotherapy followed by IMRT as a boost in combination with chemotherapy treatment for high-grade gliomas: prognostic factors and outcomes. <b>2010</b> , 9, 337-343	
749	Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients. <b>2010</b> , 152, 1189-96	10
748	Ultrasound-guided operations in unselected high-grade gliomas--overall results, impact of image quality and patient selection. <b>2010</b> , 152, 1873-86	91

747	Molecular genetics, imaging and treatment of oligodendroglial tumours. <b>2010</b> , 152, 1815-25	8
746	The role of temozolomide in neuro-oncology. <b>2010</b> , 3, 15-17	
745	Radiologic response assessment during anti-angiogenic therapy of malignant glioma: a case report. <b>2010</b> , 3, 28-29	1
744	Radiotherapy of glioblastoma. <b>2010</b> , 3, 12-14	
743	Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. <b>2010</b> , 1, 638-55	167
742	Immune therapeutic targeting of glioma cancer stem cells. <b>2010</b> , 5, 217-27	27
741	MGMT promoter methylation in malignant gliomas. <b>2010</b> , 5, 161-5	52
740	Predictors of surgical site infection in glioblastoma patients undergoing craniotomy for tumor resection. <b>2022</b> , 1-8	0
739	Diterpenoid DGA induces apoptosis via endoplasmic reticulum stress caused by changes in glycosphingolipid composition and inhibition of STAT3 in glioma cells. <b>2022</b> , 205, 115254	0
738	Impact of new molecular criteria on diagnosis and survival of adult glioma patients. <b>2022</b> , 13, 299-305	0
737	Case Report of Oral Temozolomide Therapy by Total Gastrectomy Patient. <b>2021</b> , 47, 380-386	0
736	Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. <b>2022</b> , 4,	1
735	Cell cultures in assessing radioresistance of glioblastomas. <b>2022</b> , 86, 126	0
734	Proteomics of Extracellular Vesicle in Glioblastoma. <b>2022</b> , 10, 207	0
733	Chemotherapeutic Protocols for the Treatment of Neurological Cancer. <b>2022</b> , 307-320	0
732	Stereotactic radiosurgery of radioresistant glioblastomas. The ways of overcoming radioresistance of hypoxic tumors. <b>2022</b> , 30, 25-40	0
731	Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy. <b>2022</b> , 3, 177-188	1
730	The differential usage of molecular machinery in brain cancer patients with iron-enriched glioma environments. <b>2022</b> , 8, 030-035	1

729	Radiosensitizing effect of MEK-inhibition in glioblastoma in vitro and in vivo.	0
728	Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells. <b>2022</b> , 12,	0
727	Adolescent and Young Adult Glioma: Systematic Review of Demographic, Disease and Treatment Influences on Survival.	1
726	Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition.	0
725	Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later. <b>2022</b> , 14, 5192	0
724	Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields). <b>2022</b> , 14, 5177	0
723	Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). <b>2022</b> , 13,	0
722	Feasibility of awake brain surgery in glioblastoma patients with severe aphasia: Five case illustrations. 1-20	0
721	Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma. <b>2022</b> , 10, 2590	0
720	CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma.	0
719	Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients. <b>2022</b> , 160, 253-263	0
718	Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas: a retrospective population based study. <b>2022</b> , 22,	0
717	Incidence of ischemic complications and technical nuances of arteries preservation for insular gliomas resection. 9,	0
716	Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. <b>2022</b> , 11, 5855	0
715	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. <b>2022</b> , 23, 1566-1589	1
714	Lrig1 regulates the balance between proliferation and quiescence in glioblastoma stem cells. 10,	1
713	Cytoskeletal Protein Palladin in Adult Gliomas Predicts Disease Incidence, Progression, and Prognosis. <b>2022</b> , 14, 5130	0
712	Model-free dynamic contrast-enhanced MRI analysis: differentiation between active tumor and necrotic tissue in patients with glioblastoma.	0

711	Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study. <b>2022</b> , 11, 6052	0
710	Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.	0
709	Temozolomide in aggressive pituitary tumours and pituitary carcinomas. <b>2022</b> , 101713	1
708	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. <b>2022</b> , 12, 1426	0
707	Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape. 13,	0
706	Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. <b>2022</b> , 14, 4942	0
705	Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. <b>2022</b> , 11, 5961	0
704	Irreversible Electroporation Mediates Glioma Apoptosis via Upregulation of AP-1 and Bim: Transcriptome Evidence. <b>2022</b> , 12, 1465	0
703	Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?.	0
702	Co Transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF- $\beta$ <b>2022</b> ,	0
701	Trotabresib (CC90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.	0
700	Preclinical gene therapy in glioblastoma multiforme: Using olfactory ensheathing cells containing a suicide gene. <b>2022</b> , 121132	0
699	Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance. <b>2022</b> , 12, 1625	0
698	Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge. <b>2022</b> , 14, 4827	2
697	Single-cell analysis characterizes non-enhancing region of recurrent high-grade glioma.	0
696	The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma. <b>2022</b> , 14, 4910	0
695	Glioma cancer stem cells modulating the local tumor immune environment. 15,	0
694	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.	2

- 693 DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices. 0
- 692 A Novel Prognostication System for Spinal Metastasis Patients Based on Network Science and Correlation Analysis. **2022**, 0
- 691 Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients. **2022**, 12, 1670 0
- 690 Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers. **2022**, 65, 13813-13832 0
- 689 Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma. **2022**, 22, 0
- 688 The Use of Photodynamic Therapy in the Treatment of Brain Tumors—A Review of the Literature. **2022**, 27, 6847 2
- 687 Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres. **2022**, 22, 0
- 686 The translome of Glioblastoma multiforme. 0
- 685 Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis. 2
- 684 The Ketogenic Diet: Considerations for Cancer Survivorship. 0
- 683 Multispectral fluorine-19 MRI enables longitudinal and noninvasive monitoring of tumor-associated macrophages. **2022**, 14, 2
- 682 Preservation of the Hypoxic Transcriptome in Glioblastoma Patient-Derived Cell Lines Maintained at Lowered Oxygen Tension. **2022**, 14, 4852 0
- 681 Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment. 0
- 680 Dosimetric Predictors Of Toxicity In A Randomized Study Of Short-Course Vs. Conventional Radiotherapy For Glioblastoma. **2022**, 0
- 679 Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome. 0
- 678 Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not. 0
- 677 Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. **2022**, 14, 5108 3
- 676 NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells. 0



675	Debunking the debulking in glioma surgery.	0
674	Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma. <b>2022</b> , 8,	2
673	Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. <b>2022</b> , 29, 8222-8234	0
672	Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.	0
671	New Insights into Glioma Frequency Maps: From Genetic and Transcriptomic Correlate to Survival Prediction.	0
670	Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin. <b>2022</b> , 23, 11629	1
669	Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?. <b>2022</b> , 14, 4960	2
668	Inhibition of human glioblastoma multiforme cells by 10,11-dehydrocurvularin through the MMP-2 and PI3K/AKT signaling pathways. <b>2022</b> , 175348	0
667	Chronotherapy: Circadian Rhythms and Their Influence in Cancer Therapy. <b>2022</b> , 14, 5071	2
666	Targeting tumour-intrinsic neural vulnerabilities of glioblastoma.	0
665	Electric field responsive nanotransducers for glioblastoma. <b>2022</b> , 8,	0
664	A Mass Spectrometry Imaging and Lipidomic Investigation Reveals Aberrant Lipid Metabolism in the Orthotopic Mouse Glioma. <b>2022</b> , 100304	0
663	Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy. <b>2022</b> , 23, 12499	0
662	Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.	0
661	Effectiveness of 6D couch with daily cone beam computed tomography in reducing PTV margins for glioblastoma multiforme. 1-6	0
660	Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas. 9,	0
659	Targeting integrin $\alpha$ as potential strategy for radiochemosensitization of glioblastoma.	0
658	Medical Device Advances in the Treatment of Glioblastoma. <b>2022</b> , 14, 5341	1

- 657 A Conjugate between Lqh-8/6, a Natural Peptide Analogue of Chlorotoxin, and Doxorubicin Efficiently Induces Glioma Cell Death. **2022**, 10, 2605 ○
- 656 Enhanced Cytotoxic Effects of Arenite in Combination with Active Bufadienolide Compounds against Human Glioblastoma Cell Line U-87. **2022**, 27, 6577 ○
- 655 Prognostic Factors of Survival in Glioblastoma Multiforme Patients: A Retrospective Study. **2022**, 12, 2630 ○
- 654 Editorial comment: Radiogenomics of glioblastoma: shifting the focus from tumor cells to immune microenvironment. ○
- 653 Natural killer cell immunotherapy in glioblastoma. **2022**, 13, ○
- 652 A phase 2 clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. ○
- 651 Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. **2022**, ○
- 650 Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood-Brain Tumour Barrier. **2022**, 14, 2231 ○
- 649 Advances in immunotherapy for glioblastoma multiforme. 13, ○
- 648 Transcriptome Analysis Identifies Accumulation of Natural Killer Cells with Enhanced Lymphotoxin- $\beta$  Expression during Glioblastoma Progression. **2022**, 14, 4915 ○
- 647 AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. **2022**, 11, ○
- 646 Oleic acid-bound FABP7 drives glioma cell proliferation through regulation of nuclear lipid droplet formation. ○
- 645 CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation. ○
- 644 Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus. **2022**, 14, 2433 ○
- 643 Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma. **2022**, 14, 5386 ○
- 642 CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. **2022**, 185, 106510 ○
- 641 Elucidating the cellular uptake mechanisms of heptamethine cyanine dye analogues for their use as an anticancer drug-carrier molecule for the treatment of glioblastoma. ○
- 640 Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. **2022**, 23, 1409-1418 2

639	Smart chlorotoxin-functionalized liposomes for sunitinib targeted delivery into glioblastoma cells. <b>2022</b> , 77, 103908	0
638	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. 13,	0
637	Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy. <b>2022</b> , 351, 739-751	0
636	Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial. <b>2022</b> , 24, S4-S15	0
635	Modulation of Autophagy is a Potential Strategy for Enhancing the Anti-Tumor Effect of Mebendazole in Glioblastoma Cells. <b>2022</b> , 30, 616-624	1
634	Bioinformatic Analysis of Kynurenine Pathway Enzymes and Their Relationship with Glioma Hallmarks. <b>2022</b> , 12, 1054	1
633	Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications. <b>2022</b> , 12, 3869	0
632	Yeast-derived vacuoles as a novel carrier with enhanced hCMEC/D3 cell monolayer penetration. 2200393	0
631	Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma. 12,	0
630	Survival and functional recovery of primary cortical neurons exposed to actinomycin D. <b>2022</b> , 636, 132-139	0
629	CHI3L1 predicted in malignant entities is associated with glioblastoma immune microenvironment. <b>2022</b> , 245, 109158	0
628	CSNK1D is associated with stemness and invasiveness in glioblastoma. <b>2022</b> , 240, 154187	0
627	Application of biomaterials for glioblastoma treatment: Promises, advances, and challenges. <b>2022</b> , 33, 104562	0
626	PUF60 promotes glioblastoma progression through regulation of EGFR stability. <b>2022</b> , 636, 190-196	0
625	Brain Tumour Image Segmentation Using Deep Networks. 7-12	0
624	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <b>2022</b> , 35, 803-813	2
623	Magnetic resonance imaging in the diagnosis of breast cancer metastases in the brain (a brief review of the literature).	0
622	Prognostic differences and implications on treatment strategies between butterfly glioblastoma and glioblastoma with unilateral corpus callosum infiltration. <b>2022</b> , 12,	0

- 621 Immune landscape of isocitrate dehydrogenase stratified human gliomas. ○
- 620 Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. **2022**, 14, 5494 ○
- 619 Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. **2022**, 14, 5522 ○
- 618 Probabilistic edge inference of gene networks with markov random field-based bayesian learning. 13, ○
- 617 Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment. **2022**, 23, 13818 ○
- 616 Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review. **2022**, 17, ○
- 615 Ensemble learning for glioma patients overall survival prediction using pre-operative MRIs. ○
- 614 Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation in BNCT of Brain-Tumor-Model Rats Ex Vivo Imaging of BPA Using MALDI Mass Spectrometry Imaging. **2022**, 12, 1786 1
- 613 Surgical cytoreduction of deep-seated high-grade glioma through tubular retractor. **2022**, 1-12 ○
- 612 A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status. ○
- 611 Temporal muscle thickness as an independent prognostic marker in glioblastoma patients systematic review and meta-analysis. **2022**, 45, 3619-3628 ○
- 610 Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. ○
- 609 Polymeric Chloroquine as an Effective Antimigration Agent in the Treatment of Pancreatic Cancer. ○
- 608 Comparing tumor microRNA profiles of patients with long- and short-term-surviving glioblastoma. **2022**, 27, 1
- 607 Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). ○
- 606 DHODH inhibition impedes glioma stem cell proliferation, induces DNA damage, and prolongs survival in orthotopic glioblastoma xenografts. ○
- 605 Noninvasive approaches to detect methylation-based markers to monitor gliomas. **2022**, 4, ii22-ii32 1
- 604 A Rapid Late Enhancement MRI Protocol Improves Differentiation between Brain Tumor Recurrence and Treatment-Related Contrast Enhancement of Brain Parenchyma. **2022**, 14, 5523 ○

603	LncRNA as potential biomarker and therapeutic target in glioma.	0
602	Challenges in glioblastoma research: focus on the tumor microenvironment. <b>2022,</b>	0
601	Therapeutic efficacy of <sup>166</sup> Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model. 12,	0
600	Applications of nanobodies in brain diseases. 13,	0
599	Brain Tumor Networks in Diffuse Glioma.	2
598	Recent advances in cold atmospheric plasma (CAP) for breast cancer therapy.	2
597	Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics— prospective multicenter cohort study. <b>2022, 15,</b>	0
596	Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02. <b>2022,</b>	0
595	BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review. <b>2022, 20, 1193-1202.e6</b>	0
594	The Efficacy and Safety of Adjuvant Lomustine to Chemotherapy for Recurrent Glioblastoma: A Meta-analysis of Randomized Controlled Studies. <b>2022, 45, 162-167</b>	0
593	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. 13,	0
592	Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates.	1
591	Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for CAR-T cell therapy.	0
590	Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.	1
589	Pediatric Brain Tumors in the Molecular Era: Updates for the Radiologist. <b>2022,</b>	0
588	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. 12,	0
587	A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration. <b>2022,</b>	0
586	Anti-cancer effect of targeting fibroblast activation protein alpha in glioblastoma through remodeling macrophage phenotype and suppressing tumor progression.	0

585	Particulate Matters Affecting lncRNA Dysregulation and Glioblastoma Invasiveness: In Silico Applications and Current Insights.	1
584	Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?. <b>2022</b> , 14, 5510	0
583	2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus. <b>2022</b> , 14, 5611	2
582	Advances in molecular biomarkers and liquid biopsy in gliomas. <b>2022</b> , 4, ii15-ii21	0
581	Metabolomics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Etoposide. <b>2022</b> , 23, 13940	1
580	Association of antidepressant drug use with outcome of patients with glioblastoma.	0
579	FUTURE-GB: functional and ultrasound-guided resection of glioblastoma in a two-stage randomised control trial. <b>2022</b> , 12, e064823	0
578	Immersion bioprinting of hyaluronan and collagen bioink-supported 3D patient-derived brain tumor organoids.	0
577	Engineering Energy-Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell-Based Immunotherapy. 2200234	0
576	Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.	1
575	Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients. 13,	0
574	Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis. 12,	0
573	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. 13,	0
572	Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study.	0
571	Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. <b>2022</b> , 114619	1
570	Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.	0
569	The use of temozolomide in paediatric metastatic pheochromocytoma/paraganglioma: A case report and literature review. 13,	0
568	Epstein-barr Virus Negative Primary Central Nervous System Lymphoma Developed after Treatment of Glioblastoma: A Case Report. <b>2022</b> , 9, 395-400	0

567	An Insight into Embryogenesis Interruption by Carbon Nitride Dots: Can They Be Nucleobase Analogs?.	0
566	Circular RNA circPTPRF promotes the progression of GBM via sponging miR-1208 to up-regulate YY1. <b>2022</b> , 22,	0
565	High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy. <b>2022</b> , e11783	0
564	Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres.	0
563	Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. <b>2022</b> , 19,	0
562	Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells. <b>2022</b> , 27, 7968	0
561	Image-localized Biopsy Mapping of Brain Tumor Heterogeneity: A Single-Center Study Protocol.	0
560	Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors. <b>2022</b> , 29, 8846-8861	1
559	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma.	7
558	MT1-MMP Expression Levels and Catalytic Functions Dictate LDL Receptor-Related Protein-1 Ligand Internalization Capacity in U87 Glioblastoma Cells. <b>2022</b> , 23, 14214	0
557	Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.	0
556	Central nervous system tumors. <b>2022</b> , 211-235	0
555	Treatment of Adult Gliomas: A Current Update. <b>2022</b> , 15,	0
554	Immunotherapy for a patient with high-grade glioblastoma. <b>2022</b> , 11, 37	0
553	Immunotherapeutic Strategies for Glioma Treatment. <b>2022</b> ,	0
552	Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. <b>2023</b> , 630, 122436	1
551	RAAGR2-Net: A brain tumor segmentation network using parallel processing of multiple spatial frames. <b>2023</b> , 152, 106426	0
550	PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment. <b>2023</b> , 353, 63-76	0

- 549 Epigenetic basis for PARP mutagenesis in glioblastoma: A review. **2023**, 938, 175424 ○
- 548 Guggulsterone inhibits migration and invasion through proteasomal and lysosomal degradation in human glioblastoma cells. **2023**, 938, 175411 ○
- 547 The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer. **2023**, 114, 109581 ○
- 546 Streptogramin A derivatives as mitochondrial translation inhibitors to suppress glioblastoma stem cell growth. **2023**, 246, 114979 1
- 545 Antitumor Mechanisms of Elemene in Specific Cancers. **2023**, 117-147 ○
- 544 Role of COL6A2 in malignant progression and temozolomide resistance of glioma. **2023**, 102, 110560 ○
- 543 Impact of EGFR289T/V mutation on relapse pattern in glioblastoma. **2023**, 8, 100740 ○
- 542 Transfer RNA-derived small RNAs (tsRNAs) sequencing revealed a differential expression landscape of tsRNAs between glioblastoma and low-grade glioma. **2023**, 855, 147114 ○
- 541 Imaging characterization of an adult H3 K27M-altered diffuse midline glioma of the medulla oblongata with a confounding steroid response. **2023**, 18, 788-793 ○
- 540 Polymeric Nanoparticles to Target Glioblastoma Tumors. **2022**, 329-349 ○
- 539 Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients survival. **2022**, 14, 175883592211276 ○
- 538 Safeness of sodium fluorescein administration in neurosurgery: Case-report of an erroneous very high-dose administration and review of the literature. **2022**, 2, 101703 1
- 537 Glioblastoma Antigen Expression for Tumor Targeting. **2022**, ○
- 536 Cystic glioblastoma: A systematic review and meta-analysis of characteristics and outcomes. **2022**, 2, 101692 ○
- 535 Glioblastoma: the current state of the problem. **2019**, 10, 28-35 2
- 534 Effect of Sodium Fluorescein Use on Surgical Outcomes and Survival in Cases with High Graded Glial Tumor : A retrospective study. ○
- 533 Glioblastoma PET/MRI: kinetic investigation of [18F]rhPSMA-7.3, [18F]FET and [18F]fluciclovine in an orthotopic mouse model of cancer. ○
- 532 Visualising spatial heterogeneity in glioblastoma using imaging habitats. 12, ○



- 531 Microglia-Derived Olfactomedin-like 3 Is a Potent Angiogenic Factor in Primary Mouse Brain Endothelial Cells: A Novel Target for Glioblastoma. **2022**, 23, 14613 ○
- 530 Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations. **ONCORDE. 2022**, ○
- 529 Increasing Ciliary ARL13B Expression Drives Active and Inhibitor-Resistant SMO and GLI into Glioma Primary Cilia. ○
- 528 High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac - workflow and initial experience with daily adapt-to-position (ATP) MR guidance: A first report. 12, ○
- 527 Irigenin inhibits glioblastoma progression through suppressing YAP/Hatenin signaling. 13, 1
- 526 Isoginkgetin: A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy. **2022**, 27, 8335 ○
- 525 Upregulated FKBP1A Suppresses Glioblastoma Cell Growth via Apoptosis Pathway. **2022**, 23, 14935 ○
- 524 A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. **2022**, 10, 2977 ○
- 523 Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma. Volume 14, 3245-3269 ○
- 522 Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database. **2022**, 101, e32042 ○
- 521 Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. 13, 1
- 520 Cost Matrix of Molecular Pathology in Glioma: Towards AI-Driven Rational Molecular Testing and Precision Care for the Future. **2022**, 10, 3029 ○
- 519 DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. **2022**, 23, 14672 ○
- 518 Glucose and Inositol Transporters, SLC5A1 and SLC5A3, in Glioblastoma Cell Migration. **2022**, 14, 5794 ○
- 517 Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas: a radiation oncologist's perspective. ○
- 516 Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Publish Ahead of Print, ○
- 515 Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration. **2022**, 12, 1153 1
- 514 Prognostic Factors for Survival of Patients with Glioblastoma in the Southern Region of Morocco. **2022**, 10, ○

- 513 Predicting BloodBrain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation. ○
- 512 The role of [18F]fluorodopa positron emission tomography in grading of gliomas. **2022**, 160, 577-589 ○
- 511 Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study. 12, ○
- 510 Photodynamic therapy for malignant brain tumors in children and young adolescents. 12, ○
- 509 Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. **2022**, 14, 5679 ○
- 508 Assessment and prediction of glioblastoma therapy response: challenges and opportunities. 1
- 507 Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. **2022**, 41, 1
- 506 Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis. **2022**, 11, 7514 ○
- 505 The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation. **2022**, 9, ○
- 504 CHRDL1 Regulates Stemness in Glioma Stem-like Cells. **2022**, 11, 3917 ○
- 503 Characteristics of Focused Ultrasound Mediated Blood-Brain Barrier Opening in Magnetic Resonance Images. ○
- 502 Epigenetic regulation of radioresistance: insights from preclinical and clinical studies. 1-17 ○
- 501 Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy. ○
- 500 Siderol Inhibits Proliferation of Glioblastoma Cells and Acts Synergistically with Temozolomide. **2022**, 10, 3216 ○
- 499 Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. **2022**, 10, 3205 1
- 498 Sequential and Hybrid PET/MRI Acquisition in Follow-Up Examination of Glioblastoma Show Similar Diagnostic Performance. **2023**, 15, 83 ○
- 497 Tumor Microenvironment and Microvascular Density in Human Glioblastoma. **2023**, 12, 11 1
- 496 Imaging of pediatric spine and spinal cord tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper. ○

495	Intraoperative Neurophysiologic Monitoring and Mapping of the Motor System During Surgery for Supratentorial Lesions Under General Anesthesia. <b>2023</b> , 427-436	o
494	The Radiogenomic and Spatiogenomic Landscapes of Glioblastoma, and their Relationship to Oncogenic Drivers.	o
493	Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. 10,	o
492	ET1 Peptide Sensitizes Glioma Cells to Temozolomide in a Glioblastoma Organoid Platform.	o
491	Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.	o
490	Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study. <b>2022</b> , 17,	o
489	Treatment with quercetin increases Nrf2 expression and neuronal differentiation of sub ventricular zone derived neural progenitor stem cells in adult rats..	o
488	N6-Isopentenyladenosine Impairs Mitochondrial Metabolism through Inhibition of EGFR Translocation on Mitochondria in Glioblastoma Cells. <b>2022</b> , 14, 6044	o
487	Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.	4
486	Impact of extent of resection on survival on Glioblastoma, IDH-wildtype, WHO grade 4 (WHO 2021). Systematic review and meta-analysis. <b>2022</b> ,	o
485	Safe administration of temozolomide in end-stage renal disease patients. 107815522211319	o
484	Photodynamic therapy in glioblastoma: Detection of intraoperative inadvertent 5-ALA mediated photodynamic therapeutical effect after gross total resection. 12,	1
483	Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization.	o
482	Laser interstitial thermal therapy for the treatment of primary and metastatic brain tumors: a systematic review and meta-analysis. <b>2022</b> ,	o
481	Racial disparities in recommendations for surgical resection of primary brain tumours: a registry-based cohort analysis. <b>2022</b> , 400, 2063-2073	o
480	Prognostic value of anoikis-related genes revealed using multi-omics analysis and machine learning based on lower-grade glioma features and tumour immune microenvironment.	o
479	A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases. <b>2022</b> , 14, 6264	o
478	Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers. <b>2022</b> , 29, 9928-9955	o

- 477 Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease. 9, ○
- 476 Targeted alpha therapy for glioblastoma. 9, ○
- 475 Cell senescence-associated genes predict the malignant characteristics of glioblastoma. **2022**, 22, ○
- 474 Prognostic factors affecting outcome of multifocal or multicentric glioblastoma: A scoping review. 1-11 ○
- 473 FBXO42 activity is required to prevent mitotic arrest, spindle assembly checkpoint activation, and lethality in glioblastoma and other cancers. ○
- 472 Impact of tumour characteristics and cancer treatment on cerebrovascular mortality after glioma diagnosis: Evidence from a population-based cancer registry. 12, ○
- 471 Glioblastoma cells have increased capacity to repair radiation-induced DNA damage after migration to the olfactory bulb. **2022**, 22, ○
- 470 Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas. **2022**, 53, E16 ○
- 469 Electricity-Assisted Cancer Therapy: From Traditional Clinic Applications to Emerging Methods Integrated with Nanotechnologies. 2200143 ○
- 468 Advances in co-opting anti-depressant drugs in glioma therapy. **2022**, 3, 100837 ○
- 467 Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas. **2022**, 9, 18-29 ○
- 466 Single-Cell Analysis of 5-ALA Intraoperative Labeling Specificity for Glioblastoma. ○
- 465 Federated learning enables big data for rare cancer boundary detection. **2022**, 13, 1
- 464 Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution. **2022**, 20, ○
- 463 Treatment of Orthotopic U251 Human Glioblastoma Multiforme Tumors in NRG Mice by Convection-Enhanced Delivery of Gold Nanoparticles Labeled with the  $\beta$ Particle-Emitting Radionuclide,  $^{177}\text{Lu}$ . ○
- 462  $^{18}\text{F}$ -FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. ○
- 461 Systematic characterization and biological functions of non-coding RNAs in glioblastoma. ○
- 460 Modulation of Genes and MicroRNAs in the Neurospheres of Glioblastoma Cell Lines U343 and T98G Induced by Ionizing Radiation and Temozolomide Therapy. **2022**, ○

- 459 Central Nervous System Ischemia Associated with Bevacizumab: An Analysis of the Japanese Adverse Drug Event Report Database. **2022**, 45, 1805-1811 ○
- 458 BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. ○
- 457 Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. 12, ○
- 456 Characterization of Glioblastoma Cells Response to Regorafenib. **2022**, 14, 6193 ○
- 455 Intersections of Ubiquitin-Proteasome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities. **2022**, 11, 4063 ○
- 454 Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, [windowofopportunity](#) study. 1
- 453 Survival analysis in high-grade glioma: The role of salvage surgery. **2022**, ○
- 452 A Prospective Randomized Comparative Study Between 60 Gy vs. 50 Gy Dose Radiotherapy with Concurrent Chemotherapy in Locally Advanced Unresectable Oesophageal Cancer; tertiary rural Indian cancer centre experience. ○
- 451 Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines. ○
- 450 Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. 12, ○
- 449 Modulatory activity of ADNP on the hypoxia-induced angiogenic process in glioblastoma. **2022**, 62, ○
- 448 Non-invasive Detection of Brain Gliomas Using Plasma Cell-free DNA 5-Hydroxymethylcytosine Sequencing. ○
- 447 Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles. 2200142 ○
- 446 Molecular Recognition and In Vivo Detection of Temozolomide and 5-Aminoimidazole-4-carboxamide for Glioblastoma Using Near-Infrared Fluorescent Carbon Nanotube Sensors. ○
- 445 Stelletin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. 2205529 1
- 444 Current Indications for Intraarterial Chemotherapy in Neurointerventional Surgery. ○
- 443 Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26. ○
- 442 A co-formulation of Interferons alpha2b and gamma distinctively targets Cell Cycle in the glioblastoma-derived cell line U-87MG. ○

441	Intraoperative ventricular opening has no effect on complication development following BCNU wafer implantation for malignant glioma. <b>2022</b> ,	0
440	Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data. <b>2022</b> , 14, 6180	0
439	Evaluation of different tumor delineation strategies in patients with glioblastoma receiving standard chemoradiation: impact of reduced treatment volumes on patterns of recurrence and radiation dose to healthy brain tissue. <b>2022</b> ,	0
438	Conventional and emerging treatments of astrocytomas and oligodendrogliomas.	0
437	NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity. <b>2022</b> , 14, 6065	1
436	Expanding our knowledge of brain tumor overall survival trends at a global scale.	0
435	BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. <b>2022</b> , 13,	1
434	Periostin promotes EMT via inhibition of RIN1-mediated endocytosis of EGFR in gliomas. <b>2022</b> , 1,	0
433	Extracellular vesicles in the glioblastoma microenvironment: A diagnostic and therapeutic perspective. <b>2022</b> , 101167	0
432	Three-Dimensional Cell Culture Systems in Pediatric and Adult Brain Tumor Precision Medicine. <b>2022</b> , 14, 5972	0
431	Gene Therapy for High Grade Glioma: The Clinical Experience. 1-17	0
430	Aggressive migration in acidic pH of a glioblastoma cancer stem cell line in vitro is independent of ASIC and KCa3.1 ion channels, but involves phosphoinositide 3-kinase.	1
429	Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma.	0
428	Impact of epigenetic reprogramming on antitumor immune responses in glioma. <b>2023</b> , 133,	0
427	The translome of Glioblastoma multiforme.	0
426	Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.	0
425	Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis. <b>2023</b> , 13,	0
424	Surgery of Intramedullary Spinal Cord Tumors. <b>2022</b> , 36, 132-140	0

- 423 Recent Advances in Brain Tumour Therapy Using Electrospun Nanofibres. **2022**, ○
- 422 The Role of Neuro-Inflammation and Innate Immunity in Pathophysiology of Brain and Spinal Cord Tumors. **2023**, 41-49 ○
- 421 Reconciling the Contemporary Molecular Diagnosis of Glioblastoma With Past Clinical Trial Data. ○
- 420 New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor  $\beta$ ) based on computational study for high-grade glioma therapy. 16, ○
- 419 Injectable local drug delivery systems for glioblastoma: a systematic review and meta-analysis of progress to date. ○
- 418 Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression. 13, ○
- 417 Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. **2023**, 4, 100877 ○
- 416 Signaling pathways in brain tumors and therapeutic interventions. **2023**, 8, ○
- 415 Spinal Metastasis in a Patient with Supratentorial Glioblastoma with Primitive Neuronal Component: A Case Report with Clinical and Molecular Evaluation. **2023**, 13, 181 ○
- 414 The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. **2023**, 14, ○
- 413 The Dual Role of DNA Repair Protein MGMT in Cancer Prevention and Treatment. **2023**, 103449 ○
- 412 Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway. ○
- 411 The Epidemiology of Brain and Spinal Cord Tumors. **2023**, 19-39 ○
- 410 Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. **2023**, 73-84 ○
- 409 A Comparison of Three Different Deep Learning-Based Models to Predict the MGMT Promoter Methylation Status in Glioblastoma Using Brain MRI. ○
- 408 Enhanced Glycolysis Confers Resistance Against Photon but Not Carbon Ion Irradiation in Human Glioma Cell Lines. Volume 15, 1-16 ○
- 407 Non-operable glioblastoma: proposition of patient-specific forecasting by image-informed poromechanical model. ○
- 406 Key Clinical Principles in the Management of Glioblastoma. ○

405	Genetic evolution and cellular interactions within the tumour microenvironment determine glioblastoma progression. 12, 52	0
404	Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG). 13,	1
403	Functional genomic analysis of adult and pediatric brain tumor isolates.	0
402	Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. 13,	0
401	Sex differences in drug effects and/or toxicity in oncology. <b>2023</b> , 100152	0
400	Targeted therapies in patients with newly diagnosed glioblastoma [a systematic meta-analysis of randomized clinical trials.	0
399	Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. <b>2023</b> , 12, 717	0
398	Therapy with oncolytic viruses: progress and challenges.	2
397	Fluoride in the Central Nervous System and Its Potential Influence on the Development and Invasiveness of Brain Tumours[A Research Hypothesis. <b>2023</b> , 24, 1558	0
396	Hypoxia-Induced Autophagy Is Involved in Radioresistance via HIF1A-Associated Beclin-1 in Glioblastoma Multiforme. <b>2023</b> , 9, e12820	0
395	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. 12,	0
394	CASP4 can be a diagnostic biomarker and correlated with immune infiltrates in gliomas. 12,	0
393	Patterns of failure in glioblastoma multiforme following Standard (60´Gy) or Short course (40´Gy) radiation and concurrent temozolomide.	0
392	Upstaging and Downstaging in Gliomas[Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. <b>2023</b> , 13, 197	0
391	Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. <b>2023</b> , 22,	1
390	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <b>2023</b> , 51-72	0
389	Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort. 13,	0
388	Therapy Defining at Initial Diagnosis of Primary Brain Tumor[Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. <b>2023</b> , 11, 128	0



- 387 Combining Multi-Shell Diffusion with Conventional MRI Improves Molecular Diagnosis of Diffuse Gliomas with Deep Learning. **2023**, 15, 482 ○
- 386 Palliative care in brain tumors. **2023**, 69-80 ○
- 385 MRI radiomic features of peritumoral edema may predict the recurrence sites of glioblastoma multiforme. 12, ○
- 384 ProNGF Expression and Targeting in Glioblastoma Multiforme. **2023**, 24, 1616 ○
- 383 Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma. **2023**, 36, 100872 ○
- 382 Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects. **2023**, 248, 115054 ○
- 381 Photodynamic therapy for glioblastoma: A light at the end of the tunnel. **2023**, 13, 100161 ○
- 380 Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by  $\beta$ -tocopherol succinate micelles for the treatment of glioblastoma. **2023**, 5, 100147 ○
- 379 Deciphering the Clinical Trials of Immunotherapy in Glioblastoma: What a Neuroradiologist Needs to Know. **2022**, 12, 176-187 ○
- 378 High expression of NLRP12 predicts poor prognosis in patients with intracranial glioma. **2023**, 86, 88-97 ○
- 377 Systemic Treatment in Glioblastoma. ○
- 376 Biomimetic Nanosensitizers Combined with Noninvasive Ultrasound Actuation to Reverse Drug Resistance and Sonodynamic-Enhanced Chemotherapy against Orthotopic Glioblastoma. **2023**, 17, 421-436 1
- 375 Hotspot on 18F-FET PET/CT to Predict Aggressive Tumor Areas for Radiotherapy Dose Escalation Guiding in High-Grade Glioma. **2023**, 15, 98 ○
- 374 Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients. **2023**, 12, 178 ○
- 373 Diffusion-weighted imaging and arterial spin labeling radiomics features may improve differentiation between radiation-induced brain injury and glioma recurrence. ○
- 372 Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study. **2023**, 12, 196 ○
- 371 Utility of the Cerebral Organoid Glioma  $\mu$ LICO Model for Screening Applications. **2023**, 12, 153 ○
- 370 ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. ○

- 369 Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. **2022**, 12, ○
- 368 Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review. **2022**, 101, e32477 ○
- 367 Tumor sound, auditory cues, and tissue pathology in glioma surgery: a proof-of-concept study. **2022**, 1-9 ○
- 366 The Heterogeneous Cellular States of Glioblastoma Stem Cells Revealed by Single Cell Analysis. ○
- 365 Delayed, Progressive Multivessel Occlusion After Resection of a Recurrent Glioma. **2022**, ○
- 364 Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625. 13, ○
- 363 Boron Neutron Capture Therapy for Recurrent Glioblastoma Multiforme: Imaging Evaluation of a Case With Long-Term Local Control and Survival. **2023**, ○
- 362 Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. **2023**, 15, 880 ○
- 361 Implementing multiphysics models in FEniCS: Viscoelastic flows, poroelasticity, and tumor growth. **2023**, 100074 ○
- 360 Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. Volume 16, 71-86 ○
- 359 Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses. **2023**, 15, 360 ○
- 358 Prognostic model for predicting overall survival in patients with glioblastoma: an analysis based on the SEER database. 108155892211471 ○
- 357 Predictive model of language deficit after removing glioma involving language areas under general anesthesia. 12, ○
- 356 Tumor immunology. **2023**, 245-452 ○
- 355 Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study. 1-9 ○
- 354 Defining a Correlative Transcriptional Signature Associated with Bulk Histone H3 Acetylation Levels in Adult Glioblastomas. **2023**, 12, 374 ○
- 353 Development of Advanced Nanomaterials for Multifunctional Devices: Insights into a Novel Concept of Personalized Medicine. **2023**, 4, 35-36 ○
- 352 Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. **2023**, 14, ○

- 351 Glioblastom hos voksne. **2023**, 0
- 350 Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy. 0
- 349 Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. **2023**, 161, 147-153 0
- 348 Preclinical Models of Low-Grade Gliomas. **2023**, 15, 596 0
- 347 Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL. **2023**, 0
- 346 Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status. **2023**, 15, 760 1
- 345 Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. **2023**, 14, 0
- 344 GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status. **2023**, 15, 587 0
- 343 Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. **2023**, 14, 0
- 342 Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma. **2023**, 64, 94 0
- 341 Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas. **2023**, 6, e2253285 0
- 340 Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas. 0
- 339 Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. **2023**, 15, 1
- 338 Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization. **2023**, 24, 2496 0
- 337 Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review. **2023**, 13, 159 0
- 336 Aquaporins and Ion Channels as Dual Targets in the Design of Novel Glioblastoma Therapeutics to Limit Invasiveness. **2023**, 15, 849 1
- 335 Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF- $\kappa$ B pathways. 0
- 334 Multimodal and Multiparametric Neuroimaging of Gliomas. **2023**, 3027-3054 0

- 333 Spinal metastasis from pediatric supratentorial glioblastoma: Is it the price of an extended survival? An interesting case and review of literature. **2023**, 0 ○
- 332 Fundamentals of Dendritic Cells and Their Role in Cancer. **2023**, 1-24 ○
- 331 Neurosurgical Applications of Magnetic Hyperthermia Therapy. **2023**, ○
- 330 Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022. ○
- 329 Surgeon experience in glioblastoma surgery of the elderly: multicenter, retrospective cohort study. ○
- 328 Pseudoprogession versus true progression in patients with glioblastoma: A multiapproach analysis. **2023**, 109486 ○
- 327 MRI-derived radiomics to guide post-operative management of glioblastoma: Implication for personalized radiation treatment volume delineation. 10, ○
- 326 Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. 12, ○
- 325 Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. **2023**, 335-367 ○
- 324 A Prospective Study of Longitudinal Risks of Cognitive Deficit for People Undergoing Glioblastoma Surgery Using a Tablet Computer Cognition Testing Battery: Towards Personalized Understanding of Risks to Cognitive Function. **2023**, 13, 278 ○
- 323 Honokiol-Loaded Nanoemulsion for Glioblastoma Treatment: Statistical Optimization, Physicochemical Characterization, and an In Vitro Toxicity Assay. **2023**, 15, 448 ○
- 322 Added Value of Scintillating Element in Cerenkov-Induced Photodynamic Therapy. **2023**, 16, 143 ○
- 321 The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells. ○
- 320 Perilesional resection technique of glioblastoma: intraoperative ultrasound and histological findings of the resection borders in a single center experience. 1
- 319 TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt. **2023**, 28, ○
- 318 Tumor Treating Fields delivered via electromagnetic induction have varied effects across glioma cell lines and electric field amplitudes. ○
- 317 A Comparison of MGMT Testing by MSP and qMSP in Paired Snap-Frozen and Formalin-Fixed Paraffin-Embedded Gliomas. **2023**, 13, 360 ○
- 316 Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. **2023**, 28, 1283 ○

- 315 Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2'-Deoxyguanosine Methylations in DNA. **2023**, 15, 716 ○
- 314 The Efficacy and Safety of Intraoperative Radiotherapy in the Treatment of Recurrent High-Grade Glioma: A Single-Center Prospective Study. **2023**, ○
- 313 Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. Publish Ahead of Print, ○
- 312 Metronomic Temozolomide in Heavily Pretreated Patients with Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: a Large Real-life Mono-institutional Study. **2023**, ○
- 311 An image-informed Cahn-Hilliard Keller-Segel multiphase field model for tumor growth with angiogenesis. **2023**, 445, 127834 ○
- 310 Deep Learning Applications in Perfusion MRI: Recent Advances and Current Challenges. **2022**, 26, 246 1
- 309 The Effect of Radiotherapy on Neurogenic Speech and Language Disorders of Patients with Primary Brain Tumour in the Early Period. ○
- 308 Physical Sciences in Cancer: Recent Advances and Insights at the Interface. **2023**, 301-328 ○
- 307 Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. ○
- 306 DNA Alkylation Damage by Nitrosamines and Relevant DNA Repair Pathways. **2023**, 24, 4684 ○
- 305 A mathematical model of brain tumor. ○
- 304 Lowering the computational barrier: Partially Bayesian neural networks for transparency in medical imaging AI. 5, ○
- 303 Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. ○
- 302 FZD1/KLF10-hsa-miR-4762-5p/miR-224-3p-circular RNAs axis as prognostic biomarkers and therapeutic targets for glioblastoma: a comprehensive report. **2023**, 16, ○
- 301 Combining organotypic tissue culture with multi-color fluorescence light-sheet microscopy (OTCxLSFM) as a novel tool to study glioma invasion/migration. ○
- 300 Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?. ○
- 299 Quantitative Evaluation of Stem-like Markers of Human Glioblastoma Using Single-Cell RNA Sequencing Datasets. **2023**, 15, 1557 1
- 298 Long-Term Survival of Patients With Glioblastoma of the Pineal Gland: A ChatGPT-Assisted, Updated Case of a Multimodal Treatment Strategy Resulting in Extremely Long Overall Survival at a Site With Historically Poor Outcomes. **2023**, ○

- 297 Differential Transcriptome Responses in Human THP-1 Macrophages Following Exposure to T98G and LN-18 Human Glioblastoma Secretions: A Simplified Bioinformatics Approach to Understanding Patient-Glioma-Specific Effects on Tumor-Associated Macrophages. **2023**, 24, 5115 ○
- 296 The Glioma-IRE project [Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach. **2023**, 21, ○
- 295 Case report: Radiographic complete response of radiation-induced glioblastoma to front-line radiotherapy: A report and molecular characterization of two unique cases. 14, ○
- 294 Impact of age and gender on glioblastoma onset, progression, and management. **2023**, 211, 111801 ○
- 293 Prognostic evaluation of patients with glioblastoma using a new score prediction model. **2023**, ○
- 292 Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. **2023**, 24, 6998 ○
- 291 Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy. **2023**, 49, 102663 ○
- 290 The Evolution of Laser-Induced Thermal Therapy for the Treatment of Gliomas. **2023**, 34, 199-207 ○
- 289 Technical Aspects of Motor and Language Mapping in Glioma Patients. **2023**, 15, 2173 ○
- 288 Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival. ○
- 287 PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma. **2023**, 11, 1148 ○
- 286 Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. 14, ○
- 285 MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation. **2023**, 15, 2253 ○
- 284 PPRX-1701, a nanoparticle formulation of 6?-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models. **2023**, 101019 ○
- 283 CAR T-cells to treat brain tumors. **2023**, 196, 76-98 ○
- 282 Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. **2023**, 39, 100894 ○
- 281 Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. **2023**, 357, 161-174 ○
- 280 Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment. **2023**, 638, 122924 ○

- 279 High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With 18F-GE-180. **2023**, 8, 101185 ○
- 278 Recurrence analysis of glioblastoma cases based on distance and dose information. **2023**, 183, 109600 ○
- 277 Development, characterization and in vitro cytotoxicity of kaempferol-loaded nanostructured lipid carriers in glioblastoma multiforme cells. **2023**, 226, 113309 ○
- 276 RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. **2023**, 557, 216078 ○
- 275 SNORD17-mediated KAT6B mRNA 2ED-methylation regulates vasculogenic mimicry in glioblastoma cells. ○
- 274 Neuro-Oncology in Women. **2023**, 41, 331-342 ○
- 273 Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). **2023**, 23, ○
- 272 From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. **2023**, 196, 114777 ○
- 271 Platycodin D suppresses proliferation, migration, and invasion of human glioblastoma cells through regulation of Skp2. **2023**, 948, 175697 ○
- 270 Insight into the transcription factors regulating Ischemic stroke and glioma in response to shared stimuli. **2023**, 92, 102-127 ○
- 269 Study protocol: PreOperative Brain Irradiation in Glioblastoma (POBIG) IA phase I trial. **2023**, 39, 100585 ○
- 268 Possibilities of using navigational transcranial magnetic stimulation as an element of radiotherapy preparation of patients with brain tumors: a pilot study. **2023**, 13, 102-108 ○
- 267 Headache And Right Arm Weakness. **2022**, 63-68 ○
- 266 Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. **2023**, 294, 122006 ○
- 265 Natural Killer Cell-Based Immunotherapy against Glioblastoma. **2023**, 24, 2111 ○
- 264 Glioblastoma Spheroid Invasion through Soft, Brain-Like Matrices Depends on Hyaluronic AcidCD44 Interactions. 2203143 ○
- 263 Comparison of Near-Infrared Imaging Agents Targeting the PTPmu Tumor Biomarker. ○
- 262 Rapid progression of subcutaneous glioblastoma: A case report and literature review. 13, ○

- 261 Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. ○
- 260 Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma. **2023**, 161, 515-523 ○
- 259 Newly Diagnosed Adult Basal Ganglia Gliomas Treated With Laser Interstitial Thermal Therapy: A Comparative Cohort With Needle Biopsy. **2023**, 24, 383-390 ○
- 258 Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. **2023**, 41, 305-317 ○
- 257 Single-cell spatial immune landscapes of primary and metastatic brain tumours. **2023**, 614, 555-563 1
- 256 Proteomic analysis predicts anti-angiogenic resistance in recurrent glioblastoma. **2023**, 21, ○
- 255 Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma. **2023**, 18, e0274400 ○
- 254 Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy. **2023**, 16, 227 ○
- 253 Comparison of EPI DWI and STEAM DWI in Early Postoperative MRI Controls After Resection of Tumors of the Central Nervous System. ○
- 252 Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. **2023**, 21, 120-129 ○
- 251 Bio-Prospecting of Crude Leaf Extracts from Thirteen Plants of Brazilian Cerrado Biome on Human Glioma Cell Lines. **2023**, 28, 1394 ○
- 250 Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. **2023**, 18, e0281166 ○
- 249 MUC17 mutations are associated with poor prognosis in both adult low-grade glioma and glioblastoma patients. ○
- 248 Mitoferrin-1 Promotes Proliferation and Abrogates Protein Oxidation via the Glutathione Pathway in Glioblastoma. **2023**, 12, 349 ○
- 247 Functional Graphene for Peritumoral Brain Microenvironment Modulation Therapy in Glioblastoma. 2208227 ○
- 246 A feasibility, safety, and efficacy evaluation of supervised aerobic and resistance exercise for patients with glioblastoma undertaking adjuvant chemoradiotherapy. ○
- 245 Communication in the context of glioblastoma treatment: A qualitative study of what matters most to patients, caregivers and health care professionals. 026921632311525 ○
- 244 Cancer Stem Cell and Aggressiveness Traits Are Promoted by Stable Endothelin-Converting Enzyme-1c in Glioblastoma Cells. **2023**, 12, 506 ○



- 243 Non-coding RNAs as Genetic Biomarkers for the Diagnosis, Prognosis, Radiosensitivity, and Histopathologic Grade of Meningioma. **2023**, ○
- 242 Temozolomide Chronotherapy in Glioma: A Systematic Review. **2023**, 30, 1893-1902 ○
- 241 A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma. **2023**, 9, 362-374 ○
- 240 Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. **2023**, 24, 3199 ○
- 239 LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma. **2023**, 23, ○
- 238 Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. ○
- 237 Advancements and Technical Considerations for Extracellular Vesicle Isolation and Biomarker Identification in Glioblastoma. **2023**, Publish Ahead of Print, ○
- 236 Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. **2023**, 15, 1027 ○
- 235 Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24(S),25-epoxycholesterol production. **2023**, 30, 214-229.e18 ○
- 234 Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer. **2023**, 355, 248-258 ○
- 233 Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy. **2023**, 9, ○
- 232 Immunotoxin-CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. **2023**, 15, ○
- 231 Charged particle therapy for high-grade gliomas in adults: a systematic review. **2023**, 18, ○
- 230 Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?. **2023**, 12, 535 ○
- 229 Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model. **2023**, 355, 343-357 ○
- 228 Single-Cell Analysis of Unidirectional Migration of Glioblastoma Cells Using a Fiber-Based Scaffold. **2023**, 6, 765-773 ○
- 227 IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. **2023**, 11, e006239 ○
- 226 The Immunology of Brain Tumors. **2023**, ○

- 225 An initial study on the predictive value using multiple MRI characteristics for Ki-67 labeling index in glioma. **2023**, 21, ○
- 224 Evaluation of Possible Neobavaisoflavone Chemosensitizing Properties towards Doxorubicin and Etoposide in SW1783 Anaplastic Astrocytoma Cells. **2023**, 12, 593 ○
- 223 Adrenoreceptors in Human Cancers. **2023**, 24, 3671 ○
- 222 Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research. **2023**, 11, 527 ○
- 221 Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. **2023**, 15, 1194 ○
- 220 Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro. **2023**, 24, 3760 ○
- 219 The effect of Azo-dyes on glioblastoma cells in vitro. **2023**, 30, 103599 ○
- 218 Advances in NK cell therapy for brain tumors. **2023**, 7, ○
- 217 Comparison of healthcare utilization and life-sustaining interventions between patients with glioblastoma receiving palliative care or not: A population-based study. 026921632311525 ○
- 216 Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. **2023**, 15, ○
- 215 Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial. **2023**, 15, 1239 ○
- 214 Modeling glioblastoma complexity with organoids for personalized treatments. **2023**, 29, 282-296 ○
- 213 Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme. ○
- 212 Chronotherapy in Glioblastoma: state of the art and future perspectives. **2023**, 89, 104470 ○
- 211 The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. **2023**, 14, 501 ○
- 210 Recurrent glioblastoma metastatic to the lumbar vertebra: A case report and literature review: Surgical oncology. 13, ○
- 209 CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement. **2023**, 15, 1249 ○
- 208 Urinary 8-hydroxy-2'-deoxyguanosine levels are elevated in patients with IDH1-wildtype glioblastoma and are associated with tumor recurrence in gliomas. **2023**, 124, 103463 ○

- 207 Reconstruction of the Corticospinal Tract in Patients with Motor-Eloquent High-Grade Gliomas Using Multilevel Fiber Tractography Combined with Functional Motor Cortex Mapping. **2023**, 44, 283-290 ○
- 206 RTA dh404 Induces Cell Cycle Arrest, Apoptosis, and Autophagy in Glioblastoma Cells. **2023**, 24, 4006 ○
- 205 Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting. **2023**, 8, ○
- 204 P21 Overexpression Promotes Cell Death and Induces Senescence in Human Glioblastoma. **2023**, 15, 1279 ○
- 203 PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. **2023**, 35, 517-534.e8 ○
- 202 Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications. **2023**, 15, 1268 ○
- 201 Association between systemic immune-inflammation index (SII) and survival outcome in patients with primary glioblastoma. **2023**, 102, e33050 ○
- 200 Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. **2023**, 23, ○
- 199 Impact of extent of resection and adjuvant therapy in diffuse gliomas of the spine. **2023**, ○
- 198 TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. **2023**, 11, e006121 ○
- 197 Assessment of Treatment Response to Dendritic Cell Vaccine in Patients with Glioblastoma using a Multiparametric MRI-Based Prediction Model. ○
- 196 A Simple 3D Cell Culture Method for Studying the Interactions between Human Mesenchymal Stromal/Stem Cells and Patients Derived Glioblastoma. **2023**, 15, 1304 ○
- 195 Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation. **2023**, 13, 299 ○
- 194 Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination. ○
- 193 Immunohistochemical detection of stem cell markers, transcription factors and PD-L1 in malignant gliomas in adults patients. **2021**, 16, 42-50 ○
- 192 Locally implantable nanofibre meshes by sustained release of temozolomide for combined thermo-chemotherapy to treat glioblastoma. **2023**, 47, 5816-5824 ○
- 191 Nanotechnological advancements in the brain tumor therapy: a novel approach. **2022**, 13, 531-557 ○
- 190 Glioblastoma and Other Primary Brain Malignancies in Adults. **2023**, 329, 574 ○

- 189 Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma. **2023**, 5, ○
- 188 A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories. **2023**, 2023, 1-27 ○
- 187 Oncolytic virus therapy for malignant gliomas: entering the new era. **2023**, 23, 269-282 ○
- 186 Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging. **2023**, 18, ○
- 185 Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. **2023**, 13, 383 ○
- 184 Imidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger during Tumor Therapy in Human Hematopoietic Stem Cells. **2023**, 28, 2008 ○
- 183 Is surgical resection predict overall survival in frail patients with glioblastoma, IDH-wildtype?. **2023**, 69, 101417 ○
- 182 Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance. ○
- 181 Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review. **2023**, 23, ○
- 180 The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. ○
- 179 Evaluation of Baculoviruses as Gene Therapy Vectors for Brain Cancer. **2023**, 15, 608 ○
- 178 High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis. **2023**, 18, ○
- 177 CART Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. **2023**, 15, 1414 ○
- 176 Carboxylated graphene quantum dots-mediated photothermal therapy enhances drug-membrane permeability, ROS production, and the immune system recruitment on 3D glioblastoma models. **2023**, 14, ○
- 175 Perspective Chapter: Glioblastoma of the Corpus Callosum. ○
- 174 Introductory Chapter: Significant Updates for Brain Tumors to the 2021 WHO Classification of the CNS Tumors (WHO CNS5) and Clinical Overview [Molecular Translation of the Brain Tumors. ○
- 173 Isolation of Cells from Glioblastoma Multiforme Grade 4 Tumors for Infection with Zika Virus prME and ME Pseudotyped HIV-1. **2023**, 24, 4467 ○
- 172 Top advances of the year: Neuro-oncology. ○

- 171 Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylatedMGMTgene promoter: RACTAC, a Phase II multicenter single-arm clinical trial. ○
- 170 Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy. ○
- 169 Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line. **2023**, 14, ○
- 168 Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. **2023**, 13, ○
- 167 Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. **2023**, 18, 181-198 ○
- 166 Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. 14, ○
- 165 The Influence of Ethnicity on Survival from Malignant Primary Brain Tumours in England: A Population-Based Cohort Study. **2023**, 15, 1464 ○
- 164 Clinical Outcomes for High-Risk WHO Grade II Glioma Patients Treated with Upfront TMZ- based Chemoradiotherapy. ○
- 163 Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes. **2023**, 13, 362 ○
- 162 Systems Medicine for Precise Targeting of Glioblastoma. ○
- 161 Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. ○
- 160 The Impact of Extent of Ablation on Survival of Patients With Newly Diagnosed Glioblastoma Treated With Laser Interstitial Thermal Therapy: A Large Single-Institutional Cohort. **2023**, Publish Ahead of Print, ○
- 159 LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells. ○
- 158 Simulated Adaptive Radiotherapy for Shrinking Glioblastoma Resection Cavities on a Hybrid MRI-linear Accelerator. **2023**, 15, 1555 ○
- 157 A rare case of H3K27-altered diffuse midline glioma with multiple osseous and spinal metastases at the time of diagnosis. **2023**, 23, ○
- 156 Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?. **2023**, 15, 1561 ○
- 155 Prognosis of MGMT-Positive Gene in Patients with Brain Tumors of Grade III and Grade IV. ○
- 154 TRIM56 acts through the IQGAP1-CDC42 signaling axis to promote glioma cell migration and invasion. **2023**, 14, ○

- 153 Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. ○
- 152 Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. **2023**, 24, 5016 ○
- 151 Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. **2023**, 12, ○
- 150 Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity. **2023**, 12, 2061 ○
- 149 Carbon Nanotubes-Based Anticancer Nanomedicine. **2023**, 907-937 ○
- 148 Effect of Polyunsaturated Fatty Acids on Temozolomide Drug-Sensitive and Drug-Resistant Glioblastoma Cells. **2023**, 11, 779 ○
- 147 Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report. **2023**, 244, 154399 ○
- 146 Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. ○
- 145 Short-Interval, Low-Dose [<sup>177</sup>Lu]LuProstate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma. **2023**, 48, e217-e218 ○
- 144 High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma. **2023**, 13, ○
- 143 Treatment Patterns and Outcomes of Patients with Grade 4 Glioma Treated with Radiation during the COVID-19 Pandemic. **2023**, 30, 3091-3101 ○
- 142 Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges. ○
- 141 Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1. **2023**, 324, C1039-C1052 ○
- 140 Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1). **2023**, 210, 115487 ○
- 139 The protocol for the consensus of Chinese experts on glioma multidisciplinary team management. **2022**, 5, 130 ○
- 138 Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. **2023**, 41, 678-692.e7 ○
- 137 Metabolic delineation of IDH1 wild-type Glioblastoma surgical anatomy: how to plan the tumor extent of resection. ○
- 136 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. **2023**, 12, 843 ○

- 135 A pilot study on metabolomic characterization of human glioblastomas and patient plasma . ○
- 134 Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study. **2023**, ○
- 133 Oncological and functional neurosurgery: Perspectives for the decade regarding diffuse gliomas. **2023**, ○
- 132 Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma. **2023**, 9, 633-646 ○
- 131 Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy. ○
- 130 Dosimetric comparison of pencil beam scanning proton therapy with or without multi-leaf collimator versus volumetric-modulated arc therapy for treatment of malignant glioma. **2023**, ○
- 129 Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition. **2023**, 11, ○
- 128 Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report. **2023**, 13, 514 ○
- 127 lncRNA TRHDE-AS1 correlated with genomic landscape and clinical outcome in glioma. ○
- 126 Aminobenzofuran-containing analogues of proximicins exhibit higher antiproliferative activity against human UG-87 glioblastoma cells compared to temozolomide. **2023**, 13, 8420-8426 ○
- 125 Nucleolin promotes angiogenesis and endothelial metabolism along the onco-fetal axis in the human brain vasculature. ○
- 124 Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma. **2023**, 15, 1745 ○
- 123 Investigate the possibility of using phosphorescence in clinical oncology as an early prognostic test in detecting brain carcinogenesis. ○
- 122 Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma. **2023**, 15, 928 ○
- 121 Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. **2023**, 12, 897 ○
- 120 Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains. ○
- 119 Locomotion Outcome Improvement in Mice with Glioblastoma Multiforme after Treatment with Anastrozole. **2023**, 13, 496 ○
- 118 A Systematic Review and Meta-Analysis of Supramarginal Resection versus Gross Total Resection in Glioblastoma: Can We Enhance Progression-Free Survival Time and Preserve Postoperative Safety?. **2023**, 15, 1772 ○

- 117 Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics. **2023**, 165, 1075-1085 ○
- 116 Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. **2023**, 24, 5665 ○
- 115 Impact of abdominal obesity on the risk of glioma development in patients with diabetes: A nationwide population-based cohort study in Korea. **2023**, 18, e0283023 ○
- 114 Penetrative and Sustained Drug Delivery Using Injectable Hydrogel Nanocomposites for Postsurgical Brain Tumor Treatment. **2023**, 17, 5435-5447 ○
- 113 Interstitial photodynamic therapy for newly diagnosed glioblastoma. **2023**, 162, 217-223 ○
- 112 mRNA aggregates harness danger response for potent cancer immunotherapy. ○
- 111 Antineoplastic Nature of WWOX in Glioblastoma Is Mainly a Consequence of Reduced Cell Viability and Invasion. **2023**, 12, 465 ○
- 110 LINC01393, a Novel Long Non-Coding RNA, Promotes the Cell Proliferation, Migration and Invasion through MiR-128-3p/NUSAP1 Axis in Glioblastoma. **2023**, 24, 5878 ○
- 109 Targeting Glioblastoma-Associated Macrophages for Photodynamic Therapy Using AGuIX<sup>®</sup>-Design Nanoparticles. **2023**, 15, 997 ○
- 108 Over one year of survival difference between distinct cohorts of glioblastoma patients. ○
- 107 Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment. **2023**, 24, 5910 ○
- 106 VAV3 regulates glioblastoma cell proliferation, migration, invasion and cancer stem-like cell self-renewal. **2023**, 27, ○
- 105 Data-driven spatio-temporal modelling of glioblastoma. **2023**, 10, ○
- 104 STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. **2023**, 14, ○
- 103 ChatGPT in glioma patient adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?. ○
- 102 Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. **2023**, 24, 6184 ○
- 101 Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch<sup>®</sup>): a systematic review. ○
- 100 New perspectives: glioma in adult patients. 030089162311597 ○



- 99 Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway. **2023**, 27, ○
- 98 An integrative survival analysis and a systematic review of the cerebellopontine angle glioblastomas. **2023**, 13, ○
- 97 Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma. **2023**, 14, ○
- 96 Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. **2023**, 15, ○
- 95 Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. **2023**, 23, ○
- 94 Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. **2023**, 18, ○
- 93 Demographic variations and time to initiation of adjunct treatment following surgical resection of anaplastic astrocytoma in the United States: a National Cancer Database analysis. **2023**, 162, 199-210 ○
- 92 Palliative Care. **2023**, 223-238 ○
- 91 Combined Effects of Focused Ultrasound and Photodynamic Treatment for Malignant Brain Tumors Using C6 Glioma Rat Model. **2023**, 64, 233 ○
- 90 Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. **2023**, 24, e161-e171 ○
- 89 Clinical utility of intraoperative arterial spin labeling for resection control in brain tumor surgery at 3 T. ○
- 88 Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future. ○
- 87 Machine Learning Model to Identify Prognostic Factors in Glioblastoma: A SEER-Based Analysis. ○
- 86 Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression. **2023**, 15, 2008 ○
- 85 Prognostic and predictive impact of abnormal signal volume evolution early after chemoradiotherapy in glioblastoma. ○
- 84 Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update. **2023**, 24, 6375 ○
- 83 Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. ○
- 82 Metrology and visualization analysis of literatures related to tumor immunotherapy based on CiteSpace. ○

- 81 Natural history of spinal cord metastasis from brain glioblastomas. ○
- 80 TCF12 Deficiency Impairs the Proliferation of Glioblastoma Tumor Cells and Improves Survival. **2023**, 15, 2033 ○
- 79 Neural Stem Cells as Potential Glioblastoma Cells of Origin. **2023**, 13, 905 ○
- 78 Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbisIMS. **2023**, 95, 5994-6001 ○
- 77 Non-operable glioblastoma: Proposition of patient-specific forecasting by image-informed poromechanical model. **2023**, 4, 100067 ○
- 76 Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma. **2023**, 6, e234149 ○
- 75 GALNT2 sustains glioma stem cells by promoting CD44 expression. **2023**, 15, 2208-2220 ○
- 74 Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?. **2023**, ○
- 73 Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood-brain barrier. **2023**, ○
- 72 Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). **2023**, 15, 2116 ○
- 71 Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies. ○
- 70 Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles. 14, ○
- 69 Sonodynamic therapy and Magnetic Resonance-guided Focused Ultrasound: new therapeutic strategy in Glioblastoma. ○
- 68 Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil. **2023**, 11, 1081 ○
- 67 The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. **2023**, 15, 1134 ○
- 66 Fourier transform infrared spectroscopic marker of glioblastoma obtained from machine learning and changes in the spectra. **2023**, 103550 ○
- 65 Experience of Using the INTRABEAM System to Determine the Safely Tolerated Dose During Intraoperative Irradiation of Malignant Gliomas. **2023**, 6, 49-59 ○
- 64 Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner. ○

- 63 The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. **2023**, 12, 27 ○
- 62 Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. ○
- 61 Updates on Role for and Efficacy of Laser Interstitial Thermal Therapy in the Management of Brain Tumors. **2023**, 3, 87-96 ○
- 60 Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. ○
- 59 Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. **2023**, 23, ○
- 58 A retrospective analysis of irinotecan and bevacizumab combination therapy in recurrent high-grade glioma and glioblastoma multiforme: Single-institute experience. **2022**, 5, 1 ○
- 57 A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. ○
- 56 Persistent Peri-Ablation Blood-Brain Barrier Opening After Laser Interstitial Thermal Therapy for Brain Tumors. **2023**, ○
- 55 High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. **2023**, 15, 2196 ○
- 54 Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes. **2023**, 9, ○
- 53 TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report. **2023**, 13, 633 ○
- 52 Differentiating glioblastoma from primary central nervous system lymphoma of atypical manifestation using multiparametric magnetic resonance imaging: A comparative study. **2023**, 9, e15150 ○
- 51 Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. **2023**, 6, e202201680 ○
- 50 Using AI to improve the molecular classification of brain tumors. **2023**, 29, 793-794 ○
- 49 Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection. ○
- 48 Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities. **2023**, 24, ○
- 47 Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. **2023**, 13, 543 ○
- 46 Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy. **2023**, 12, 1125 ○

- 45 Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. 13, ○
- 44 Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. **2023**, 21, ○
- 43 BRD4: New hope in the battle against glioblastoma. **2023**, 191, 106767 ○
- 42 Engineering Gliatrap: a biodegradable non-swelling hydrogel with tuned release of CXCL12 to attract migrating glioblastoma cells. ○
- 41 Stereotactic radiosurgery for distant punctate recurrent IDH-wild type glioblastoma: a single institution experience. ○
- 40 Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells. 14, ○
- 39 Personalised therapeutic approaches to glioblastoma: A systematic review. 10, ○
- 38 Advances in Surgical Treatment of Glioblastoma. **2023**, 13, 5501-5506 ○
- 37 Discovery and Validation of Novel LonP1 and Proteasome Inhibitor in IDH1-R132H Malignant Astrocytoma Models. ○
- 36 5-Demethylnobletin mediates cell cycle arrest and apoptosis via the ERK1/2/AKT/STAT3 signaling pathways in glioblastoma cells. 13, ○
- 35 Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article. **2023**, 10, 042-047 ○
- 34 Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?. ○
- 33 Advanced 3D Models of Human Brain Tissue Using Neural Cell Lines: State-of-the-Art and Future Prospects. **2023**, 12, 1181 ○
- 32 Live Stimulated Raman Histology for the Near-Instant Assessment of Central Nervous System Samples. ○
- 31 Integrative Rare Disease Biomedical Profile based Network Supporting Drug Repurposing, a case study of Glioblastoma. ○
- 30 Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. ○
- 29 Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. ○
- 28 Sema3C signaling is an alternative activator of the canonical WNT pathway in glioblastoma. **2023**, 14, ○

- 27 Immunotherapy in glioblastoma treatment: Current state and future prospects. 14, 138-159 ○
- 26 Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma. **2023**, 13, 685 ○
- 25 Cell Cycle-Related FAM64A Could be Activated by TGF- $\beta$  Signaling to Promote Glioma Progression. ○
- 24 Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification. **2023**, 11, 1219 ○
- 23 Identifying G6PC3 as a potential key molecule in hypoxic glucose metabolism of glioblastoma derived from the depiction of 18F-fluoromisonidazole and 18F-fluorodeoxyglucose positron emission tomography. ○
- 22 Recruitment mechanisms and therapeutic implications of tumor-associated macrophages in the glioma microenvironment. 14, ○
- 21 Chemotherapy. **2023**, 7-159 ○
- 20 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy. **2023**, 10, 496 ○
- 19 Understanding the activity of antibodydrug conjugates in primary and secondary brain tumours. ○
- 18 Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. **2023**, 147-200 ○
- 17 Unsupervised machine learning models reveal predictive markers of glioblastoma patient survival using white blood cell counts prior to initiating chemoradiation. ○
- 16 Sonication is a suitable method for loading nanobody into glioblastoma small extracellular vesicles. **2023**, 9, e15674 ○
- 15 In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment. ○
- 14 Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine. ○
- 13 The role of cytoreductive surgery in multifocal/multicentric glioblastomas. ○
- 12 Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. **2023**, ○
- 11 An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?. 13, ○
- 10 Adipose Tissue-Derived Stem Cell Extracellular Vesicles Suppress Glioblastoma Proliferation, Invasiveness and Angiogenesis. **2023**, 12, 1247 ○

- 9 Combination of local immunogenic cell death-inducing chemotherapy and DNA vaccine increases the survival of glioblastoma-bearing mice. **2023**, 50, 102681
- 8 Investigate the Possibility of Using Phosphorescence in Clinical Oncology as an Early Prognostic Test in Detecting Brain Carcinogenesis.
- 7 Deep Learning of Time-Signal Intensity Curves from Dynamic Susceptibility Contrast Imaging Enables Tissue Labeling and Prediction of Survival in Glioblastoma. **2023**, 44, 543-552
- 6 BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression.
- 5 Targeted Glioblastoma Therapy by Integrating Brain-Targeting Peptides and Corn-derived Cancer Cell-Penetrating Proteins into Nanoparticles to Cross Blood-Brain Tumor Barriers. **2023**, 100347
- 4 A novel gene, TARDBP, and the protein it encodes can predict glioma patient prognosis and establish a prediction model. **2023**, 23,
- 3 Pediatric Brain and Brainstem Tumors. **2023**, 125-140
- 2 Oxidative Stress Linking Obesity and Cancer: Is Obesity a Radical Trigger to Cancer?. **2023**, 24, 8452
- 1 A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma. **2023**, 15, 1501